Page last updated: 2024-12-05

chenodeoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chenodeoxycholic acid (CDCA) is a bile acid synthesized in the liver from cholesterol. It is a primary bile acid, meaning it is synthesized directly in the liver, unlike secondary bile acids, which are produced by bacterial metabolism in the gut. CDCA is crucial for the digestion and absorption of fats, as it helps to emulsify lipids in the small intestine. It is also involved in the regulation of cholesterol metabolism. CDCA is studied extensively due to its potential therapeutic applications. For instance, it has been used to treat cholesterol gallstones by dissolving them. It also holds promise in the treatment of liver diseases such as primary biliary cholangitis. Research continues to explore its role in other conditions like obesity and diabetes. CDCA has also been shown to have anti-inflammatory and anti-cancer effects. Its complex role in various physiological processes makes it a subject of ongoing research.'

Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID10133
CHEMBL ID240597
CHEBI ID16755
SCHEMBL ID25055
MeSH IDM0004029

Synonyms (193)

Synonym
BIDD:PXR0056
smr000857194
MLS002154253
HY-76847
AB00513822-06
leadiant (formerly chenodeoxycholic acid sigma-tau)
gtpl608
CHEBI:16755 ,
anthropodesoxycholic acid
cdca
chenix
3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid
7alpha-hydroxylithocholic acid
chenorm
xenbilox
chenofalk
(3alpha,5beta,7alpha,8xi)-3,7-dihydroxycholan-24-oic acid
5-beta-cholan-24-oic acid, 3-alpha,7-alpha-dihydroxy-
henohol
3-alpha,7-alpha-dihydroxy-5-beta-cholan-24-oic acid
chendeoxycholic acid
(3beta,7beta,8xi,9xi,14xi,17alpha)-3,7-dihydroxycholan-24-oic acid
cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)-
acido chenodeoxicholico [inn-spanish]
nsc 657949
chenodiol [usan]
chenodesoxycholsaeure [german]
cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)-
chenique acid
einecs 207-481-8
acide chenodeoxycholique [inn-french]
7-alpha-hydroxylithocholic acid
ccris 2195
acidum chenodeoxycholicum [inn-latin]
3-alpha,7-alpha-dihydroxycholanic acid
3-alpha,7-alpha-dihydroxycholansaeure [german]
nsc-657949
D00163
chenix (tn)
chenodeoxycholic acid (jp17/inn)
chenodiol (usan)
PRESTWICK2_000285
cas-474-25-9
NCGC00016387-02
SMP1_000064
PRESTWICK3_000285
BPBIO1_000210
BSPBIO_000190
AB00513822
bdbm21674
(4r)-4-[(1s,2s,5r,7s,9r,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid
chenodeoxycholic acid
474-25-9
C02528
chenodiol
3alpha,7alpha-dihydroxy-5beta-cholanic acid
chenodeoxycholate
anthropodeoxycholic acid
(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid
cholan-24-oic acid, 3,7-dihydroxy-, (3-.alpha., 5-.beta., 7-.alpha.)-
chenic acid
gallodesoxycholic acid
chenodesoxycholic acid
anthropododesoxycholic acid
chendol
chenodeoxycholic acid, >=97%
jn3 ,
LMST04010032
SPECTRUM5_002009
chenodeoxycholic acid, free acid
PRESTWICK0_000285
PRESTWICK1_000285
SPBIO_002409
HSCI1_000210
NCGC00142400-03
acid, chenique
acid, chenic
acid, gallodesoxycholic
acid, chenodeoxycholic
C-2900
0DBBBC66-0CFA-4DB9-97F4-5B1492756A02
cholanorm
nsc-757798
chenocol
fluibil
CHEMBL240597
chenossil
DB06777
chenocholic acid
HMS1568J12
NCGC00142400-04
HMS2095J12
ec 207-481-8
acide chenodeoxycholique
unii-0gei24lg0j
chenodeoxycholic acid [inn]
3-alpha,7-alpha-dihydroxycholansaeure
chenodesoxycholsaeure
acidum chenodeoxycholicum
0gei24lg0j ,
acido chenodeoxicholico
(4r)-4-[(1r,3as,3br,4r,5as,7r,9as,9bs,11ar)-4,7-dihydroxy-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-1-yl]pentanoic acid
EN300-75328
NCGC00258045-01
tox21_200491
A827222
3,7-dihydroxy-5-cholanicacid
5beta-cholanic acid-3alpha,7alpha-diol
cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)- (9ci)
BMSE000908
chenodeoxycholic acid (jp16/inn)
dtxcid40260
tox21_110412
dtxsid2020260 ,
HMS2234I22
(4r)-4-((1s,2s,7s,11s,5r,9r,10r,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo [8.7.0.0<2,7>.0<11,15>]heptadec-14-yl)pentanoic acid
chenodal
chenodiol [orange book]
ursodeoxycholic acid impurity a [ep impurity]
cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.alpha.)
chenodeoxycholic acid [who-dd]
chenodeoxycholic acid [jan]
chenodeoxycholic acid [ep impurity]
chenodiol [vandf]
chenodeoxycholic acid [mart.]
chenodiol [mi]
chenodeoxycholic acid [ep monograph]
CS-0834
CCG-220285
SCHEMBL25055
3.alpha.,7.alpha.-dihydroxy-5.beta.-cholanoic acid
chenocedon
cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.alpha.)-
3,7-dihydroxycholan-24-oic acid, (3.alpha.,5.beta.,7.alpha.)- #
3.alpha.,7.alpha.-dihydroxy-5.beta.-cholan-24-oic acid
chendal
7.alpha.-hydroxylithocholic acid
3.alpha.,7.alpha.-dihydroxy-5.beta.-cholanic acid
hekbilin
chenodex
kebilis
5.beta.-cholan-24-oic acid, 3.alpha.,7.alpha.-dihydroxy-
3.alpha.,7.alpha.-dihydroxycholanic acid
3.alpha.,7.alpha.-dihydroxycholansaeure
dihydroxy-3.alpha.,7.alpha.(5.beta.)cholanic acid
3alpha, 7alpha,-dihydroxy-5beta-cholanic acid
3alpha, 7alpha-dihydroxy-5beta-cholanoic acid
AKOS024280614
cholan-24-oic acid, 3,7-dihydroxy-, (3a,5b,7a)-
(r)-4-((3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
AB00513822_07
mfcd00064142
chenodeoxycholic acid, european pharmacopoeia (ep) reference standard
chenodeoxycholic acid, 500 mug/ml in methanol, certified reference material
(3alpha,5beta,7alpha)-3,7-dihydroxycholan-24-oic acid
(4r)-4-[(1s,2s,5r,7s,9r,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0?,?.0??,??]heptadecan-14-yl]pentanoic acid
HMS3712J12
(3a,5b,7a)-3,7-dihydroxy-cholan-24-oic acid
3a,7a-dihydroxy-5b-cholanic acid
3a,7a-dihydroxy-5b-cholan-24-oic acid
3a,7a-dihydroxy-5b-cholanate
(+)-chenodeoxycholate
(+)-chenodeoxycholic acid
3a,7a-dihydroxy-5b,14a,17b-cholanic acid
7a-hydroxy-desoxycholsaeure
(3a,5b,7a)-3,7-dihydroxy-cholan-24-oate
3a,7a-dihydroxy-5b-cholan-24-oate
3a,7a-dihydroxy-5b,14a,17b-cholanate
'(3alpha,5alpha,7beta,8alpha,17alpha)-3,7-dihydroxycholan-24-oic acid'
(3alpha,5alpha,7beta,8alpha,17alpha)-3,7-dihydroxycholan-24-oic acid
S1843
24404-86-2
AS-13636
Q419028
BRD-K18135438-001-16-7
chenodeoxycholic-acid
(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoicacid
NCGC00142400-08
acido chenodesossicolico
acidum chenodeoxycholicum (inn-latin)
acide chenodeoxycholique (inn-french)
a05aa01
3alpha,7alpha-dihydroxycholanic acid
chenodeoxycholic acid (ep monograph)
acido chenodeoxicholico (inn-spanish)
acido quenodeoxicolico
acide chenodesoxycholique
chanodasoxycholique (acide)
chenodeoxycholic acid (ep impurity)
chenodeoxycholic acid (mart.)
ursodeoxycholic acid impurity a (ep impurity)
cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)
Z1172235745

Research Excerpts

Overview

Chenodeoxycholic acid (CDCA) is a liver-formed detergent and plays an important role in the control of cholesterol homeostasis. It is an effective treatment for dissolving gallstones but experimental studies have suggested that it might be hepatotoxic.

ExcerptReferenceRelevance
"Chenodeoxycholic acid (CDCA) is a natural germination inhibitor for C. "( Studies on the Importance of the 7α-, and 12α- hydroxyl groups of N-Aryl-3α,7α,12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile.
Abel-Santos, E; Firestine, SM; Phan, J; Sharma, SK; Simon, MP; Yip, C, 2021
)
2.06
"Chenodeoxycholic acid (CDCA) is a liver-formed detergent and plays an important role in the control of cholesterol homeostasis. "( Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver.
Barbier, O; Bélanger, J; Caron, P; Grepper, S; Inaba, TT; Kaeding, J; Monté, D; Trottier, J; Verreault, M, 2006
)
2.02
"Chenodeoxycholic acid (CDCA) is an effective treatment for dissolving gallstones but experimental studies have suggested that it might be hepatotoxic. "( Effect of chenodeoxycholic acid on liver structure and function in man: a stereological and biochemical study.
Giampieri, MP; Jezequel, AM; Koch, MM; Lorenzini, I; Orlandi, F, 1980
)
2.11
"Chenodeoxycholic acid (CDCA) is a potent suppressor of the cholesterol 7alpha-hydroxylase, the rate-determining enzyme in bile acid formation."( Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects.
Axelson, M; Einarsson, C; Hillebrant, CG, 2001
)
1.29
"Chenodeoxycholic acid is an important drug for the treatment of cholesterol cholelithiasis in man. "( Toxicity of chenodeoxycholic acid in the rhesus monkey.
Chen, T; Dyrszka, H; Mosbach, EH; Salen, G, 1975
)
2.08

Effects

Chenodeoxycholic acid has been administered to 50 patients with cholelithiasis and 8 with choledocholithiasis for a period of 15 months at doses varying between 2- and 15 mg/kg/day.

ExcerptReferenceRelevance
"Chenodeoxycholic acid has a broad influence on lipid metabolism, including reducing plasma clearance of LDL. "( Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Angelin, B; Eriksson, M; Ghosh Laskar, M; Rudling, M, 2017
)
2.17
"Chenodeoxycholic acid has a broad influence on lipid metabolism, including reducing plasma clearance of LDL. "( Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Angelin, B; Eriksson, M; Ghosh Laskar, M; Rudling, M, 2017
)
2.17
"Chenodeoxycholic acid has been administered to 50 patients with cholelithiasis and 8 with choledocholithiasis for a period of 15 months at doses varying between 2- and 15 mg/kg/day. "( The medical treatment of cholesterol gallstones: experience with chenodeoxycholic acid.
Aldini, R; Barbara, L; Festi, D; Mazzella, G; Roda, A; Roda, E; Sama, C, 1976
)
1.94

Treatment

Chenodeoxycholic acid (CDCA) treatment specifically decreased both PCSK9 mRNA and protein contents. Treatment for periods ranging from 6 months to 3 years and 4 months lowered serum lathosterol and campesterol levels in parallel with cholestanol level.

ExcerptReferenceRelevance
"Chenodeoxycholic acid treatment increased plasma LDL cholesterol by ~10% as a result of reduced clearance of plasma LDL-apolipoprotein (apo)B; LDL production was somewhat reduced. "( Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Angelin, B; Eriksson, M; Ghosh Laskar, M; Rudling, M, 2017
)
2.17
"Chenodeoxycholic acid (CDCA) treatment stabilized chimeric GFP-LDLR 3'-UTR mRNA and accompanied mitogen-activated protein kinase (MAPK) activation."( Chenodeoxycholic acid stabilization of LDL receptor mRNA depends on 3'-untranslated region and AU-rich element-binding protein.
Inoue, J; Sato, R; Shimizu, M; Yashiro, T; Yokoi, Y, 2011
)
2.53
"Chenodeoxycholic acid treatment was effective in improving liver function and decreasing unusual bile acids such as 7α-hydroxy- and 7α,12α-dihydroxy-3-oxo-4-cholen-24-oic acids in serum and urine."( Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: diagnosis and bile acid profiles during chenodeoxycholic acid treatment.
Hasegawa, T; Hayashi, S; Homma, K; Hoshina, T; Ihara, K; Kimura, A; Kurosawa, T; Matsuishi, T; Mizuochi, T; Morimura, T; Nittono, H; Ohno, Y; Ohtake, A; Seki, Y; Takahashi, T; Takei, H, 2013
)
1.32
"Chenodeoxycholic acid (CDCA) treatment specifically decreased both PCSK9 mRNA and protein contents."( Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
Cariou, B; Caron, S; Costet, P; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Staels, B, 2008
)
1.07
"Chenodeoxycholic acid treatment resulted in a significant lowering of the serum triglycerides in both groups of patients."( The hypotriglyceridemic effect of chenodeoxycholic acid in type IV hyperlipemia.
Camarri, E; Marcolongo, R; Marini, G; Zaccherotti, L, 1978
)
1.26
"Chenodeoxycholic acid treatment for periods ranging from 6 months to 3 years and 4 months lowered serum lathosterol (57.7% reduction) and campesterol (57.8%) levels in parallel with cholestanol (70.8%) level, but the sitosterol level (19.7%) decreased less."( High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
Fujiyama, J; Kasama, T; Kuriyama, M; Osame, M, 1991
)
1
"Chenodeoxycholic acid treatment for two separate periods of 10 and 6 months each increased nerve conduction velocity."( Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid.
Donaghy, M; King, RH; McKeran, RO; Schwartz, MS; Thomas, PK, 1990
)
1.21
"In chenodeoxycholic acid-treated patients (n = 9), the portal venous concentration of this bile acid was increased 3-fold; total bile acids were increased about 60%."( Portal venous bile acids in cholesterol gallstone disease: effect of treatment with chenodeoxycholic and cholic acids.
Ahlberg, J; Angelin, B; Björkhem, I; Einarsson, K; Ewerth, S,
)
0.65
"Chenodeoxycholic acid treatment lowered biliary cholesterol saturation in obese gallstone patients by reducing biliary cholesterol secretion."( Bile lipid secretion in obese and non-obese individuals with and without gallstones.
Dowling, RH; Maton, PN; Murphy, GM; Reuben, A, 1985
)
0.99
"Treatment with chenodeoxycholic acid (CDCA; chenodiol) is the current standard of care."( Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen, G; Steiner, RD, 2017
)
0.79
"Treatment with chenodeoxycholic acid (CDCA) may slow the progression of the disease and reverse some symptoms in a proportion of patients."( Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.
Bartkiewicz, J; Biskup, S; Catarino, CB; Gallenmüller, C; Hörtnagel, K; Klopstock, T; Küpper, C; Seelos, K; Vollmar, C, 2018
)
0.82
"Treatment with chenodeoxycholic acid normalizes cholestanol concentrations and abrogates progression of the disease."( Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.
Aaref, S; Berginer, VM; Falik-Zaccai, TC; Gross, B; Kfir, N; Morad, K; Morkos, S, 2009
)
0.69
"Treatment with chenodeoxycholic acid resulted in a 40% reduction of HMG CoA reductase activity."( Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Ahlberg, J; Angelin, B; Einarsson, K, 1981
)
0.8
"Treatment with chenodeoxycholic acid was tried on two occasions."( Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis?
Casteels, M; Clayton, PT; Lawson, AM; Mieli-Vergani, G, 1995
)
0.63
"Treatment with chenodeoxycholic acid (CDCA) 750 mg/day orally improved neurological and biochemical abnormalities."( Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study.
Berginer, J; Berginer, VM; Korczyn, AD; Tadmor, R, 1994
)
0.63
"Oral treatment with chenodeoxycholic acid causes dissolution of cholesterol gallstones in man. "( Biliary lipid output during three meals and an overnight fast. II. Effect of chenodeoxycholic acid treatment in gallstone subjects.
Hofmann, AF; LaRusso, NF; Northfield, TC; Thistle, JL, 1975
)
0.81
"Treatment with chenodeoxycholic acid led to clinical and biochemical improvement in one patient."( 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology.
Clayton, PT; Horslen, SP; Lawson, AM; Malone, M, 1992
)
0.86
"Treatment with chenodeoxycholic acid resulted in marked clinical improvement and normalized liver function tests."( Bile acids and bile alcohols in a child with hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment.
Baginski, ES; Clayton, PT; Egestad, B; Ichimiya, H; Nazer, H; Sjövall, J, 1991
)
0.83
"Treatment with chenodeoxycholic acid reduced cerebrospinal fluid cholesterol by 34 percent and cholestanol threefold."( Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
Berginer, V; Horak, E; Horak, I; Salen, G; Shefer, S; Shore, V; Tint, GS, 1987
)
0.81
"Treatment with chenodeoxycholic acid, which suppresses abnormal bile acid synthesis in these patients, reduced plasma bile alcohol concentrations dramatically."( Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid.
Batta, AK; Batta, M; Salen, G; Shefer, S; Tint, GS, 1987
)
0.83
"Treatment with chenodeoxycholic acid, 15 mg per kg body weight per day for 3-4 weeks before surgery, decreased the mean level to 20 +/- 7 ng/ml (P greater than 0.05)."( On the possible use of the serum level of 7 alpha-hydroxycholesterol as a marker for increased activity of the cholesterol 7 alpha-hydroxylase in humans.
Akerlund, JE; Angelin, B; Björkhem, I; Einarsson, K; Ewerth, S; Reihnér, E, 1987
)
0.61
"Treatment with chenodeoxycholic acid (0.5-1.5 g/day by mouth) did not change serum cholesterol levels but did significantly reduce serum triglyceride concentrations from a pretreatment level of 118 (+/- S.E."( Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy.
Bell, GD; Dowling, RH; Lewis, B; Petrie, A, 1973
)
0.86

Toxicity

ExcerptReferenceRelevance
"To test whether hepatotoxicity occurring in National Cooperative Gallstone Study patients was caused by a toxic effect of chenodiol per se or of lithocholate caused by defective sulfation, bile samples were analyzed using a new high-performance liquid chromatography method that measures the proportions of the four individual lithocholate amidates (sulfated and unsulfated lithocholylglycine and lithocholyltaurine) and all common bile acid amidates."( The lack of relationship between hepatotoxicity and lithocholic-acid sulfation in biliary bile acids during chenodiol therapy in the National Cooperative Gallstone Study.
Converse, JL; Fisher, RL; Hofmann, AF; Lan, SP; Rossi, SS, 1991
)
0.28
" Severe adverse effects of the bile acids were not observed."( Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid.
Aydemir, U; Hasford, J; Holl, J; Pauletzki, J; Paumgartner, G; Sackmann, M; Sauerbruch, T, 1991
)
0.48
"Hypertransaminasemia is a frequent side effect during chenodeoxycholic administration for gallstone dissolution."( Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids.
Alvaro, D; Angelico, M; Attili, AF; Cantafora, A; Capocaccia, L, 1986
)
0.27
" The findings suggest that the chenodeoxycholic-ursodeoxycholic acid combination provides a safe and efficacious treatment for some cholesterol gallstones."( Gallstone dissolution treatment with a combination of chenodeoxycholic and ursodeoxycholic acids. Studies of safety, efficacy and effects on bile lithogenicity, bile acid pool, and serum lipids.
Ceryak, S; Fromm, H; Malavolti, M; Roehrkasse, R; Tunuguntla, AK, 1986
)
0.27
" When ursodeoxycholate (final concentration, 30 mumol/L or 100 mumol/L) was added to mitochondrial incubations containing chenodeoxycholate or lithocholate, the toxic effects of lipophilic bile acids on mitochondrial oxidative metabolism were partially reversed."( Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria.
Fischer, S; Krähenbühl, S; Reichen, J; Talos, C, 1994
)
0.29
"Quantitative aspects of bile acid cytotoxicity to colon cancer cell lines were investigated because of the etiological role in colon carcinogenesis attributed to the toxic effects of bile acids on colon mucosal cells."( Toxicity of bile acids to colon cancer cell lines.
Fiander, H; Latta, RK; Ross, NW; Schneider, H; Simpson, C, 1993
)
0.29
" The coupling of cell colonies with a suitable transduction device has led to the development in recent years of toxicity biosensors based on the alteration of a process or a cell metabolic function by the toxic substance under examination."( Toxicity order of cholanic acids using an immobilised cell biosensor.
Campanella, L; Favero, G; Mastrofini, D; Tomassetti, M, 1996
)
0.29
" The toxicity of 5alpha-cyprinol sulfate/chenodeoxycholic acid (9:1) and 5alpha-cyprinol sulfate was similar to each other, and the toxic effect of chenodeoxycholic acid was less."( Effect of chenodeoxycholic acid on the toxicity of 5alpha-cyprinol sulfate in rats.
Chen, SK; Deng, JF; Hwang, DF; Wang, DY; Yeh, YH, 2002
)
0.98
" To elucidate the toxic effect of snake bile acids on rats, a synthetic bile acid mixture was prepared mimicking the bile acid composition of a snake Naja naja atra bile juice."( Bile acid composition in snake bile juice and toxicity of snake bile acids to rats.
Deng, JF; Hwang, DF; Liau, MY; Noguchi, T; Wang, DY; Wu, ML; Yeh, YH, 2003
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
" Finally, we demonstrate that FXR agonists do not stimulate migration in breast cancer cell lines, an important potential adverse effect."( Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential.
Alasmael, N; Meira, LB; Mohan, R; Plant, NJ; Swales, KE, 2016
)
0.43
"Inhibition of bile salt export pump (BSEP) causes hepatic accumulation of toxic bile acid (BA), leading to hepatocyte death."( Identification of Bile Acids Responsible for Inhibiting the Bile Salt Export Pump, Leading to Bile Acid Accumulation and Cell Toxicity in Rat Hepatocytes.
Fukagai, M; Ito, K; Oizumi, K; Sekine, S; Susukida, T, 2017
)
0.46
" Obeticholic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events."( Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
Andreone, P; Bowlus, CL; Drenth, JPH; Hirschfield, GM; MacConell, L; Malecha, ES; Nevens, F; Pencek, R; Shapiro, D; Shiffman, ML; Trauner, M; Vargas, V, 2019
)
0.51
" The adverse events rate was 35%; 11."( Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
Ampuero, J; Arenas, JI; Berenguer, M; Carrión, JA; Casado, M; Conde, I; Costa-Moreira, P; De Carvalho, A; Fernández-Rodríguez, CM; Garcia Buey, L; Gomez, E; Hernández-Guerra, M; Jorquera, F; Luisa Gutiérrez, M; Macedo, G; Manuel Sousa, J; Mesquita, M; Molina, E; Morillas, RM; Olveira, A; Pérez-Fernández, E; Presa, J; Santos, A; Simón, MA; Uriz, J, 2021
)
0.62
"67 ULN) in PBC, and the adverse effects of OCA."( Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Arab, JP; Candia, R; Kulkarni, AV; Kumar, P; Padaki, NR; Premkumar, M; Reddy, DN; Sharma, M; Tevethia, HV, 2021
)
0.62
" However, 25 mg OCA led to significant adverse events and discontinuation of the drug [2."( Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Arab, JP; Candia, R; Kulkarni, AV; Kumar, P; Padaki, NR; Premkumar, M; Reddy, DN; Sharma, M; Tevethia, HV, 2021
)
0.62
"Lower doses of OCA are effective and safe in NASH and cholestatic liver disease."( Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Arab, JP; Candia, R; Kulkarni, AV; Kumar, P; Padaki, NR; Premkumar, M; Reddy, DN; Sharma, M; Tevethia, HV, 2021
)
0.62
" We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy."( Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
Abenavoli, L; Alvaro, D; Bertino, G; Brunetto, M; Calvaruso, V; Cannavò, M; Carbone, M; Cazzagon, N; Chessa, L; Claar, E; Coco, B; Colapietro, F; Cotugno, R; Cozzolongo, R; Cristoferi, L; Cuccorese, G; D'Amato, D; D'Antò, M; De Gasperi, E; De Vincentis, A; Distefano, M; Fiorini, C; Floreani, A; Frazzetto, E; Galati, G; Galli, A; Gerussi, A; Giannini, EG; Invernizzi, P; Izzi, A; Labanca, S; Lleo, A; Losito, F; Malinverno, F; Marconi, G; Marra, F; Marzioni, M; Morelli, O; Morgando, A; Mulinacci, G; Muratori, L; Niro, GA; Palermo, A; Palitti, VP; Pellicano, R; Pellicelli, A; Picardi, A; Pompili, M; Ponziani, F; Ronca, V; Rosina, F; Russello, M; Sacco, R; Saitta, C; Scaravaglio, M; Scifo, G; Simone, L; Storato, S; Terracciani, F; Tortora, A; Vanni, E; Vespasiani-Gentilucci, U; Viganò, M; Zolfino, T; Zuin, M, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"The metabolism and enterohepatic circulation of chenodeoxycholic acid (CDC), a major primary bile acid in man, has been stimulated using a multicompartmental physiological pharmacokinetic model which was previously reported and used to simulate the metabolism of cholic acid."( Simulation of the metabolism and enterohepatic circulation of endogenous chenodeoxycholic acid in man using a physiological pharmacokinetic model.
Belforte, G; Bona, B; Cravetto, C; Hofmann, AF; Molino, G, 1986
)
0.76
"The metabolism and enterohepatic circulation of deoxycholic acid (DCA), a major secondary bile acid in humans, was simulated using a linear multicompartmental physiologic pharmacokinetic model."( Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism.
Belforte, G; Bona, B; Cravetto, C; Hofmann, AF; Molino, G, 1987
)
0.27
"To compare COVs for bowel function with pharmacodynamic (PD) colonic transit geometric center (GC) as endpoints in lower FGID studies."( Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.
Burton, D; Camilleri, M; Zinsmeister, AR, 2013
)
0.39
" It was appropriate for preclinical pharmacokinetic studies of OCA."( An ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of obeticholic acid in rat plasma and its application in preclinical pharmacokinetic studies.
Hu, GX; Li, XY; Yang, F; Yuan, LJ; Zhu, SH, 2019
)
0.51
" The method was successfully validated and applied to the pharmacokinetic studies in healthy Chinese volunteers after a single oral dose administration of obeticholic acid tablets of 10 mg, and the pharmacokinetic characteristics of obeticholic acid in human were reported for the first time."( A Sensitive HPLC-MS/MS Method for Determination of Obeticholic Acid in Human Plasma: Application to a Pharmacokinetic Study in Healthy Volunteers.
Ding, L; Hu, C; Lai, Y; Li, Y; Liu, Y, 2022
)
0.72

Compound-Compound Interactions

Study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative.

ExcerptReferenceRelevance
" One hundred milimoles solution of TCA had 2-fold activity of a 25mM solution in the dissolution of both the slices and the whole concrement when it was used in combination with EDTA 4Na."( [Effect of proteolytic enzymes and bile salts combined with EDTA 4Na on the dissolution of calcium bilirubinate gallstones].
Cho, H; Shinya, F; Suzuki, N; Takahashi, W, 1987
)
0.27
"The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells."( Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009
)
0.75
" The decrease in MKC bioavailability, when administered with gliclazide, caused by probiotic treatment in healthy but not diabetic rats suggests that probiotic treatment induced MKC metabolism or impaired its absorption, only in healthy animals."( Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I, 2012
)
0.38
" This study aims to compare the response and dissolution rates between ursodeoxycholic acid (UDCA) alone or in combination with chenodeoxycholic acid (CDCA) according to stone density on computed tomography (CT) scan."( Comparison on Response and Dissolution Rates Between Ursodeoxycholic Acid Alone or in Combination With Chenodeoxycholic Acid for Gallstone Dissolution According to Stone Density on CT Scan: Strobe Compliant Observation Study.
Choi, IY; Hyun, JJ; Jung, SW; Jung, YK; Kim, CD; Kim, SY; Koo, JS; Lee, HS; Lee, JM; Lee, SW; Yeom, SK; Yim, HJ, 2015
)
0.84
"Near-infrared spectroscopy (NIRS) combined with chemometrics was used to analyze the main active ingredients including chlorogenic acid, caffeic acid, luteoloside, baicalin, ursodesoxycholic acid, and chenodeoxycholic acid in the Tanreqing injection."( Rapid analysis of the Tanreqing injection by near-infrared spectroscopy combined with least squares support vector machine and Gaussian process modeling techniques.
Li, W; Liu, S; Pan, J; Qu, H; Xue, D; Yan, X, 2019
)
0.7
"Cytochrome P450 (CYP) downregulation is a mechanism of drug-drug interaction encountered in pharmaceutical development which is difficult to evaluate in vitro because of the scarcity of evidence."( CYP1A2 Downregulation by Obeticholic Acid: Usefulness as a Positive Control for the In Vitro Evaluation of Drug-Drug Interactions.
Ishida, C; Kotake, Y; Sanoh, S, 2019
)
0.51

Bioavailability

Chenodeoxycholic acid (chenic acid) is well absorbed by the intestine. The absorption of ursodeoxy cholic acid is incomplete. In a dose-response study, a formulation with complete bioavailability was fed to 13 gallstones patients.

ExcerptReferenceRelevance
" The rate of absorption decreased from the colon to the duodenum (colon greater than ileum greater than jejunum greater than duodenum)."( Intestinal oxalate absorption. I. Absorption in vitro.
Caspary, WF, 1977
)
0.26
" At concentrations below 5 mM, the rate of absorption of bile acids was directly proportional to concentration, so that "clearance" could be calculated."( Colonic absorption of unconjugated bile acids: perfusion studies in man.
Hofmann, AF; Mekhjian, HS; Phillips, SF, 1979
)
0.26
" Ursodeoxycholic acid is well absorbed from intestine, undergoes little biotransformation during hepatic passage, and is 7-dehydroxylated by colonic bacteria."( Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid.
Makino, I; Nakagawa, S, 1978
)
0.26
"In a dose-response study, a formulation of chenodeoxycholic acid (chenic acid) with complete bioavailability was fed at doses of 0, 250, 500, 750 mg for randomized 6-week periods to 13 patients with radiolucent gallstones."( Effect of varying doses of chenodeoxycholic acid on bile lipid and biliary bile acid composition in gallstone patients: a dose-response study.
Hofmann, AF; Ott, B; Thistle, JL; Yu, PY, 1977
)
0.82
"7 mumol/24 h, indicating an intestinal absorption rate of 77."( Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage.
Raedsch, R; Rudolph, G; Stiehl, A; Walker, S, 1992
)
0.28
"Little is known about the physical state, intestinal solubilization, absorption and bioavailability of chenodeoxycholic acid used in the medical treatment of gallstones."( Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid.
Carulli, N; Dowling, RH; Loria, P; Murphy, GM; Ponz de Leon, M, 1980
)
0.7
" The studies show that delta 6-lithocholenic acid is 1) formed in colonic lumen from chenodeoxycholic and ursodeoxycholic acids, 2) well absorbed in small intestine, and 3) biotransformed in both the colonic lumen and liver."( Formation, absorption, and biotransformation of delta 6-lithocholenic acid in humans.
Albert, MB; Ceryak, S; Cohen, B; Fromm, H; Malavolti, M; Nsien, E; Setchell, KD, 1993
)
0.29
" Chenodeoxycholic acid is well absorbed by the intestine, whereas the absorption of ursodeoxycholic acid is incomplete."( Clinical pharmacokinetics of therapeutic bile acids.
Crosignani, A; Invernizzi, P; Larghi, A; Podda, M; Rodrigues, CM; Setchell, KD, 1996
)
1.2
" Since UDCA acts partly by reducing the intestinal absorption of hydrophobic endogenous bile salts and is poorly absorbed from the intestine, a multiple dose regimen has been advocated."( Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
Salemans, JM; Tangerman, A; Van Berge-Henegouwen, GP; van Buuren, HR; van de Meeberg, PC; van Erpecum, KJ; van Hattum, J; Wolfhagen, FH, 1996
)
0.29
" This study examined the possibility that paracellular transport is modulated by luminal GA, resulting in an enhanced rate of absorption in the small intestine."( Gum arabic (GA) modifies paracellular water and electrolyte transport in the small intestine.
Harper, RG; Rehman, KU; Teichberg, S; Wapnir, RA; Wingertzahn, MA, 2003
)
0.32
" Oral administration of acyclovir valylchenodeoxycholate to rats resulted in a 2-fold increase in the bioavailability of acyclovir, compared to the bioavailability after administration of acyclovir alone."( Increased acyclovir oral bioavailability via a bile acid conjugate.
Coop, A; Lentz, KA; Maeda, DY; Polli, JE; Tolle-Sander, S, 2004
)
0.32
" In conclusion, it is feasible to increase the bioavailability of UDCA to the intestine and the liver by administering active bacteria."( Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria.
Beguet, F; Cayuela, C; David, O; Gibard, C; Hermier, D; Juste, C; Lepercq, P; Michelin, R; Relano, P, 2005
)
0.33
" The absolute bioavailability of MKC was found to be low in healthy and diabetic rats (29 and 23% respectively) and was not significantly different between the two groups."( Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats.
Al-Salami, H; Boni, NS; Fawcett, JP; Golocorbin-Kon, S; Kevresan, S; Kuhajda, K; Mikov, M,
)
0.13
" It was found that gliclazide bioavailability was increased in healthy rats when coadministered with MKC, but there was no difference in glucose levels."( The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.
Al-Salami, H; Fawcett, JP; Golocorbin-Kon, S; Mikov, M; Raskovic, A; Skrbic, R,
)
0.13
" CEF oral bioavailability was increased twofold when coadministered with MKC and when encapsulated in microvesicles and ninefold when encapsulated in MKC microvesicles compared to the same CEF dose administered orally as saline solution."( Cefotaxime pharmacokinetics after oral application in the form of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate microvesicles in rat.
Arafat, M; Golocorbin-Kon, S; Lepojevic, Z; Mikov, I; Mikov, M; Sahman-Zaimovic, M; Tomic, Z,
)
0.13
"The human apical sodium-dependent bile acid transporter (ASBT) is a validated drug target and can be employed to increase oral bioavailability of various drug conjugates."( Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid.
Acharya, C; Pan, Y; Polli, JE; Swaan, PW; Zheng, X, 2010
)
0.58
" When coadministered with gliclazide, the bioavailability of MKC was reduced in healthy rats treated with probiotics but remained the same in diabetic pretreated rats."( Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I, 2012
)
0.38
" The aim of this study is to improve the oral bioavailability of DX-9065 by cyclodextrins (CyDs) capable of interfering with such interaction."( Cyclodextrins improve oral absorption of a novel factor Xa inhibitor by interfering with interaction between the drug and bile acids in rats.
Fujii, Y; Irie, T; Ishiguro, T; Sakuma, S; Takahashi, M; Uekama, K, 2013
)
0.39
" Therefore, the oral bioavailability of HP-beta-CD/PMX/DCK/P188-NE in rats was evaluated as 26."( Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect.
Byun, Y; Choi, JU; Pangeni, R; Panthi, VK; Park, JW, 2018
)
0.48
" Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration."( Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions.
Ba, B; Behl, CR; Désiré, A; Gaudin, K; Gomes, M; Kauss, T; Langlois, MH; Malick, AW; Patel, IH; Phoeung, T; Unowsky, J; White, N, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In this context, we designed a solid oral formulation of oxaliplatin (OP), a third-generation cisplatin analog, to improve oral bioavailability and investigate its application in metronomic chemotherapy."( Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer.
Byun, Y; Chang, KY; Choi, JU; Jha, SK; Kang, SH; Kweon, S; Pangeni, R; Park, JW; Subedi, L, 2020
)
0.56
"2% and 277% higher, respectively, than the oral bioavailability of free OP."( Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer.
Byun, Y; Chang, KY; Choi, JU; Jha, SK; Kang, SH; Kweon, S; Pangeni, R; Park, JW; Subedi, L, 2020
)
0.56
" A combination of sodium chenodeoxycholate and propyl gallate was used to enhance bioavailability of MEDI7219 at the site of maximal gastrointestinal absorption, targeted by enteric-coated tablets."( Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.
Balic, K; Grimsby, J; Huang, Y; Konkar, A; Liang, L; Naylor, J; Patel, C; Pechenov, S; Revell, J; Rosenbaum, AI; Subramony, JA; Tseng, L; Tyagi, P; Will, S, 2021
)
0.62

Dosage Studied

Chenodeoxycholic acid (chenic acid) with complete bioavailability was fed at doses of 0, 250, 500, 750 mg for randomized 6-week periods to 13 patients with radiolucent gallstones. After the multiple dosing of chenode Oxycholic Acid-24-14C for 6 days, beta-muricholic acid was also identified in the feces.

ExcerptRelevanceReference
" By means of electronmicroscopy we detected in the CDCA-group already with 20 mg/kg/day microstructural alterations of the liver that increased with elevation of the dosage and duration of treatment."( [The influence of chenodeoxycholic acid and ursodeoxycholic acid on the hepatic structure of the rat (author's transl)].
Korte, L; Leuschner, U; Schneider, M, 1979
)
0.59
" The major factor influencing response, provided dosage is adequate, appears to be gallstone type."( Chenotherapy for gallstone dissolution. II. Induced changes in bile composition and gallstone response.
Hofmann, AF; Klein, PD; Szczepanik, PA; Thistle, JL; Yu, PY, 1978
)
0.26
"Twenty-three patients with gallstones were treated with two dosage levels of ursodeoxycholic acid, 600 mg/day and 150 mg/day."( Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid.
Makino, I; Nakagawa, S, 1978
)
0.26
" Even a tetrafold increase of dosage in female rats produced no change in findings."( [Morphologic, animal experimental study on the question of sex specific liver lesions due to chenodesoxycholic acid].
JOCK, C; Leuschner, U, 1977
)
0.26
"In a dose-response study, a formulation of chenodeoxycholic acid (chenic acid) with complete bioavailability was fed at doses of 0, 250, 500, 750 mg for randomized 6-week periods to 13 patients with radiolucent gallstones."( Effect of varying doses of chenodeoxycholic acid on bile lipid and biliary bile acid composition in gallstone patients: a dose-response study.
Hofmann, AF; Ott, B; Thistle, JL; Yu, PY, 1977
)
0.82
" Dose-response inhibition of water transport in everted hamster jejunal segments was obtained with two long chain detergents (sodium dodecyl sulfate and dioctyl sodium sulfocuccinate), a fatty acid (ricinoleate), and dihydroxy bile salts (deoxycholate, chenodeoxycholate, and taurodeoxycholate), whereas no activity was seen with trihydroxy (cholate, glycocholate, and taurocholate) and tri-keto (dehydrocholate) bile salts."( Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity.
Bass, P; Benz, L; Cline, WS; Gullikson, GW; Lorenzsonn, V; Olsen, WA, 1977
)
0.26
" We compared the achieved findings to results obtained already beforehand by light- and electron microscopy after application of 20, 50 and 90 mg/kg body weight and day: Up to a dosage of 90 mg/kg morphological changes of the liver were only visible electron optically, from 150 mg/kg onward they could be seen light optically as well."( [Morphologic investigations on the toxicity of orally applied CDCA in the liver, gastro intestinal tract, kidney and adrenal gland of the rat (author's transl)].
Kurtz, W; Leuschner, U; Loos, R; Schneider, M, 1977
)
0.26
" These measurements could only be applied for the determination of the minimal maintenance dosage before onset of long lasting therapy after stone dissolution."( [Summary of work session 3: Drug-induced dissolution of gallstones].
Leuschner, U, 1976
)
0.26
" After the multiple dosing of chenodeoxycholic acid-24-14C for 6 days, beta-muricholic acid was also identified in the feces."( Metabolism of chenodeoxycholic acid in hamsters.
Katayama, K; Tateyama, T, 1976
)
0.9
"Both chenodeoxycholic acid, in the dosage administered for dissolution of gallstones, and cholic acid are completely conjugated during one passage through the liver."( [Conjugation of chenodeoxycholic acid and cholic acid during passage through liver].
Paumgartner, G; Preisig, R; Schultheiss, HR; v Bergmann, K, 1975
)
1.11
" In the intermediate dosage range, both factors contributed to the decreased ratio."( Effect of 17alpha-ethinylestradiol on biliary excretion of bile acids.
Watanabe, H, 1975
)
0.25
" One hundred and twelve patients with radiolucent gallstones entered the study; 54 received chenodeoxycholic acid (CDCA) and 58 ursodeoxycholic (UDCA) at dosage of 15 mg/kg/daily."( [Changes in the pattern of serum biliary acids and lipoprotein picture during therapy with biliary acids in cholesterol lithiasis].
Aggio, L; Angonese, C; Basso, D; Burlina, A; Del Favero, G; Di Mario, F; Meggiato, T; Naccarato, R; Plebani, M; Scalon, P,
)
0.35
" Factors affecting gallstone dissolution using the bile acids include the dosage and administration schedule, obesity, the stone characteristics, diet, and the duration of therapy."( Medical management of cholesterol gallstones.
Abate, MA, 1986
)
0.27
" Chenodeoxycholic acid was given in a dosage of 15 mg/kg/day from the 8th day."( Chenodeoxycholic acid therapy in erythrohepatic protoporphyria.
Baart de la Faille, H; Edixhoven-Bosdijk, A; Van den Berg, JW; Van Hattum, J; Wilson, JH, 1986
)
2.62
" When labeled CDCA was orally administered to squirrel monkeys, less than 20% of the dosed radioactivity was recovered as LCA and its further metabolites in feces over 3 days, indicating that bacterial metabolism of CDCA into LCA is strikingly less than in other animals and in humans."( Metabolism of lithocholic and chenodeoxycholic acids in the squirrel monkey.
Hamada, M; Kato, F; Suzuki, H, 1985
)
0.56
" Chenodeoxycholic acid was given to 97 patients in a dosage of 15 mg/kg of body weight per day for a period of two years."( Drug and treatment efficacy of chenodeoxycholic acid in 97 patients with cholelithiasis and increased surgical risk.
Carey, WD; Ferguson, DR; Forsythe, S; Hightower, NC; Paradis, K; Tangedahl, T; Williams, M, 1983
)
1.46
"The ability of chenodeoxycholic acid to dissolve gallstones was compared using different dosage regimens in two groups of 21 patients."( Comparison of a monitored dose with a standard dose of chenodeoxycholic acid for gallstone dissolution.
Bradley, BM; Hall, JC; Watts, JM; Whiting, MJ, 1984
)
0.87
" CDCA is well tolerated; diarrhoea (sometimes requiring dosage reduction) is the only frequent side effect."( Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.
Iser, JH; Sali, A, 1981
)
1.71
"A double-blind clinical trial comparing ursodesoxycholic acid and chenodesoxycholic acid in patients with cholesterol stones in the gall-bladder showed that ursodesoxycholic acid was superior to the older drug not so much in percentage of biliary calculi dissolved but in dosage reduction (50%) and improved clinical and biological tolerance."( [Treatment of cholesterol gallstones with ursodesoxycholic acid (author's transl)].
Bernades, P; Bertrand, L; Bouvry, M; Colin, R; Geffroy, Y; Hecht, Y; Klepping, C; Lambert, R; Levy, VG; Michel, H; Paliard, P; Paris, J; Quinton, A, 1982
)
0.26
"After review of the history and baseline laboratory studies, gallstone dissolution therapy with chenodeoxycholic acid is begun at a dosage of 500 mg/day and gradually increased to an optimum dosage of 15 mg/kg/day."( Medical therapy for gallstones. 2. Initiation and monitoring.
Carey, WD; Tangedahl, TN, 1982
)
0.48
"A dose-response study comparing ursodeoxycholic and chenodeoxycholic acid was carried out in six men with asymptomatic radiolucent gallstones present in well-visualizing gallbladders."( Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study.
Carlson, GL; Hofmann, AF; Larusso, NF; Ott, BJ; Thistle, JL; Turcotte, J, 1982
)
0.78
"In spite of many reports which suggested the efficacy of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) on cholesterol gallstone dissolution, problems still remain to be solved, such as the ideal dosage and duration of treatment to obtain maximal benefit with minimal untoward effects."( Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones.
Iwamura, K, 1982
)
0.51
" radiolucent cholesterol gallstones, functioning gallbladder, stone size, patients' cooperation--it is possible in up to 70% to dissolve gallstones completely or partially, using a therapeutic regimen of chenodeoxycholic or ursodeoxycholic acid at a dosage of 10 mg or 15 mg/kg body weight respectively."( [Internist therapy of cholelithiasis].
Riemann, JF, 1981
)
0.26
"To test whether long-term oral dosage with chenodiol (chenodeoxycholic acid) used for dissolution of cholesterol gallstones would cause impairment of small-intestinal structuree or function, ten patients were studied before and after three months of oral chenodiol administration, 15 mg/kg of body weight per day."( Effect of chenodiol on the small intestine. Unimpaired structure and function during therapy for gallstone dissolution.
Aldini, R; Barbara, L; Bazzoli, F; Casanova, S; Festi, D; Mazzella, G; Morselli, AM; Roda, A; Roda, E; Sama, C, 1981
)
0.51
"The hepatoprotective action of orally dosed putrescine was investigated using rat models of liver injury."( Protective action of putrescine against rat liver injury.
Fujiwara, K; Matsui, A; Nagoshi, S; Ohta, Y, 1994
)
0.29
"Jejunal and ileal rabbit intestinal segments were separately perfused with bile acid solutions, and dose-response curves were obtained for taurocholate, ursodeoxycholate, chenodeoxycholate, deoxycholate, and their glycoconjugates."( Intestinal absorption of bile acids in the rabbit: different transport rates in jejunum and ileum.
Aldini, R; Biagi, PL; Hrelia, S; Montagnani, M; Roda, A; Roda, E, 1996
)
0.29
" The aim of this study was to determine whether a low dosage of lactulose is able to discriminate between normal and increased permeability."( The sensitivity of the lactulose/rhamnose gut permeability test.
Brouns, F; Brummer, RJ; Deutz, NE; Geerling, BJ; van Nieuwenhoven, MA, 1999
)
0.3
" Thus, in this work, a dose-response study was carried out to investigate the in vitro cytotoxic effect of major unconjugated and tauro- (T) or glyco- (G) conjugated bile acids and to compare this as regards their ability to inhibit DNA synthesis."( Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture.
Marin, JJ; Martinez-Diez, MC; Monte, MJ; Serrano, MA, 2000
)
0.31
"5 to 2 g/d, to our knowledge the highest dosage yet reported."( Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
Anna, M; Antonio, C; Azzaroli, F; Bovicelli, L; Colecchia, A; Constance, M; Davide, F; Enrico, R; Festi, D; Francesco, A; Giovanni, N; Giuliana, S; Luciano, B; Mazzella, G; Miracolo, A; Mwangemi, C; Nicola, R; Nigro, G; Patrizia, S; Rizzo, N; Roda, E; Simonazzi, G; Simoni, P, 2001
)
0.31
" This is perhaps due to a UDCA dosage deficit."( The UDCA dosage deficit: a fate shared with CDCA.
Azzaroli, F; Ferrara, F; Festi, D; Giovanelli, S; Liva, S; Mazzella, G; Nigro, G; Roda, E, 2002
)
0.31
" Groups of healthy and alloxan-induced diabetic rats were dosed intravenously (i."( Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats.
Al-Salami, H; Boni, NS; Fawcett, JP; Golocorbin-Kon, S; Kevresan, S; Kuhajda, K; Mikov, M,
)
0.13
" Upon weaning, piglets were fasted for 16 h and then intragastrically dosed with 20 g test feed in 40 g water."( Chenodeoxycholic acid reduces intestinal permeability in newly weaned piglets.
Buurman, WA; Gerrits, WJ; Holst, JJ; Kulik, W; Moreto, M; van den Bosch, M; van der Meer, Y; van Kempen, TA, 2012
)
1.82
" Both CDCA and PGE2 contributed to TER reduction in an identical trend and a dose-response manner."( Bile acids increase alveolar epithelial permeability via mitogen-activated protein kinase, cytosolic phospholipase A2 , cyclooxygenase-2, prostaglandin E2 and junctional proteins.
Chang, SC; Chen, CS; Hsiao, YH; Hung, MH; Lee, YC; Perng, DW; Su, KC; Tseng, CM; Wu, YC, 2013
)
0.39
" T and OCA dosing in HFD rabbits both reduced TNFα liver expression and plasma levels, with a parallel increase of penile eNOS expression and responsiveness to Ach."( Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Galli, A; Maggi, M; Maneschi, E; Mannucci, E; Morelli, A; Rastrelli, G; Saad, F; Sarchielli, E; Vannelli, GB; Vignozzi, L, 2014
)
0.4
" She was started on chenodeoxycholic acid (CDCA) supplementation, which inhibits cholestanol production through a feedback mechanism, at the advised dosage of 15 mg/kg/day."( Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Bosch, AM; Huidekoper, HH; Vaz, FM; Verrips, A, 2016
)
1.07
"adequate metabolic control was achieved in an infant with CTX with CDCA supplementation at a dosage of 5 mg/kg/day and was well tolerated."( Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Bosch, AM; Huidekoper, HH; Vaz, FM; Verrips, A, 2016
)
0.75
" What is New: CDCA supplementation at the advised dosage of 15 mg/kg/day in children seems hepatoxic in infants with CTX."( Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Bosch, AM; Huidekoper, HH; Vaz, FM; Verrips, A, 2016
)
0.75
" The effect of new agents such obeticholic acid are promising, since the addition of this farnesoide-X-receptor agonist bile acid in patients with stable UDCA dosage and increased alkaline phosphatase levels results in an improvement of cholestasis as compared to placebo, with a parallel decrease of aminotransferases and immunoglobulin M, as well as one surrogate marker of bile acid synthesis."( Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés, A, 2015
)
0.42
"A reversed-phase HPLC method was developed for the simultaneous determination of ursodeoxycholic acid (UDCA) and the epimeric isomer, chenodeoxycholic acid (CDCA), in their synthetic mixtures and in tablet dosage form."( Simultaneous Determination of Ursodeoxycholic Acid and Chenodeoxycholic Acid in Pharmaceutical Dosage Form by HPLC-UV Detection.
Khairy, MA; Mansour, FR, 2017
)
0.91
" Patients were randomized and dosed with placebo (n = 23), OCA 10 mg (n = 20), or OCA 50 mg (n = 16) given as monotherapy once daily for 3 months (1 randomized patient withdrew prior to dosing)."( A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
Adorini, L; Beecher-Jones, T; Böhm, O; Chapman, R; Hirschfield, GM; Jones, D; Kowdley, KV; Luketic, V; Marschall, HU; Mason, A; Parés, A; Pencek, R; Poupon, R; Rust, C; Schramm, C; Sciacca, C; Shapiro, D; Vincent, C, 2018
)
0.48
" The effect was sustained during follow-up for 6 mo with treatment at a daily dosage of 25 mg."( Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.
Dahlerup, JF; Hvas, CL; Jørgensen, SP; Lal, S; Ott, P; Paine, P, 2018
)
0.48
" Thus, OCA dosing in a therapeutic protocol restores the balance between relaxant and contractile pathways in the lung, promoting cardiopulmonary protective actions in MCT-induced PAH."( Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
Adorini, L; Cellai, I; Comeglio, P; Corno, C; Filippi, S; Maggi, M; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
bile acidAny member of a group of hydroxy-5beta-cholanic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration.
dihydroxy-5beta-cholanic acidA hydroxy-5beta-cholanic acid carrying two hydroxy groups at unspecified positions.
C24-steroidA steroid compound with a structure based on a 24-carbon (cholane) skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761
Biochemical pathways: part I0466
Oxysterols derived from cholesterol3831

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency79.90070.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency57.98300.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency43.77470.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency43.77470.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency15.68120.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency30.98610.000221.22318,912.5098AID743035; AID743040; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.79890.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency56.87160.001022.650876.6163AID1224838; AID1224839
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency33.78580.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency61.83340.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.39020.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.55340.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency49.96900.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency24.15290.375827.485161.6524AID743220; AID743239
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.57870.000229.305416,493.5996AID743069; AID743075; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency27.62000.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency20.74140.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency41.39440.023723.228263.5986AID743222; AID743223
caspase-3Homo sapiens (human)Potency68.79890.013326.981070.7614AID1346978
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency58.37450.057821.109761.2679AID1159528
Caspase-7Cricetulus griseus (Chinese hamster)Potency68.79890.006723.496068.5896AID1346980
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
caspase-3Cricetulus griseus (Chinese hamster)Potency68.79890.006723.496068.5896AID1346980
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency51.67740.000627.21521,122.0200AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency70.83720.002319.595674.0614AID651631; AID720552
Guanine nucleotide-binding protein GHomo sapiens (human)Potency31.62281.995325.532750.1187AID624288
TAR DNA-binding protein 43Homo sapiens (human)Potency22.38721.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.60000.11007.190310.0000AID1443986
Vitamin D3 receptorHomo sapiens (human)IC50 (µMol)100.00000.00000.43746.4300AID1277414; AID1277417
Ileal sodium/bile acid cotransporterHomo sapiens (human)Ki3.30003.30006.400010.0000AID681332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)EC50 (µMol)6.71000.00080.37336.7100AID297450
Vitamin D3 receptorHomo sapiens (human)EC50 (µMol)150.00000.00000.14232.1400AID1277413; AID1277415
Alpha-2B adrenergic receptorHomo sapiens (human)EC50 (µMol)6.71000.00051.36446.7100AID297450
Alpha-2C adrenergic receptorHomo sapiens (human)EC50 (µMol)6.71000.00050.55416.7100AID297450
Retinoic acid receptor RXR-alphaMus musculus (house mouse)EC50 (µMol)16.80000.04001.71805.0000AID629094
Bile acid receptorMus musculus (house mouse)EC50 (µMol)16.80000.15202.04315.0000AID629094; AID635573
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)15.48200.02372.52598.9000AID1059690; AID1193333; AID1569580; AID1569582; AID1686017; AID1798108; AID297450; AID324923; AID592917; AID673744
Bile acid receptorHomo sapiens (human)EC50 (µMol)13.38060.00401.419110.0000AID1166181; AID1232938; AID1305701; AID1313848; AID1349338; AID1351287; AID1413747; AID1446797; AID1546885; AID1576216; AID1633315; AID1686015; AID1798109; AID1798115; AID1799080; AID240134; AID240176; AID240314; AID265705; AID267784; AID294203; AID297451; AID324925; AID388376; AID441572; AID592913; AID629055; AID662692; AID673746; AID72525; AID72526; AID72531
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (281)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (74)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaMus musculus (house mouse)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (384)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345827Human FPR1 (Formylpeptide receptors)2000Inflammation research : official journal of the European Histamine Research Society ... [et al.], Dec, Volume: 49, Issue:12
Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors.
AID1346437Human GPBA receptor (Bile acid receptor)2002Biochemical and biophysical research communications, Nov-15, Volume: 298, Issue:5
Identification of membrane-type receptor for bile acids (M-BAR).
AID1346766Human Farnesoid X receptor (1H. Liver X receptor-like receptors)1999Science (New York, N.Y.), May-21, Volume: 284, Issue:5418
Bile acids: natural ligands for an orphan nuclear receptor.
AID1346766Human Farnesoid X receptor (1H. Liver X receptor-like receptors)1999Molecular cell, May, Volume: 3, Issue:5
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID592922Induction of FXR-mediated Ostbeta mRNA expression in human HepG2 cells at 20 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1686056Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion of the administered compound including the secreted taurine conjugates at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID673747Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs relative to 10 uM CDCA2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID240134Activation of human farnesoid X receptor; range is 10-302005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Farnesoid X receptor: from structure to potential clinical applications.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1187915Agonist activity at GAL4 DNA binding domain tagged FXR ligand binding domain (unknown origin) expressed in human HepG2 cells co-expressing human human SHP gene promoter assessed as transactivation of SHP promoter driven luciferase activity at 10 uM relati2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Cryptochinones from Cryptocarya chinensis act as farnesoid X receptor agonists.
AID1233566Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 20 ug/ml by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID240176Binding affinity for human Farnesoid X receptor in FRET assay2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1412048Induction of angiogenesis in HUVEC assessed as increase in tube formation at 12.5 uM after overnight incubation by inverted microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID409882Cytotoxicity against human GBM cells at 50 uM after 48 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID680256TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 20 uM, CDCA: 200 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID1059688Selectivity ratio of EC50 for TGR5 Y89A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1852830Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID294203Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
AID441586Metabolic stability in bile fistula rat model assessed as conjugated drug level recovered in bile at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1166186Agonist activity at FXR in human HepG2 cells assessed as induction of SHP mrNA expression at 50 uM by quantitative PCR method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1852826Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID422552Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli at 100 uM by saturation transfer difference NMR spectroscopy2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID490124Lipophilicity, log P of the compound2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID1161666Agonist activity at FXR (unknown origin) expressed in human HepG2 cells assessed as stimulation of FXR response element IR1-mediated receptor transactivation at 1 uM by luciferase reporter gene assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
AID1059683Agonist activity at TGR5 E169A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1609608Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in SULT2A1 protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1233570Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 20 ug/ml by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID303502Activation of BSEP gene expression in human HepG2 cells at 25 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1398006Inhibition of lipid accumulation in mouse 3T3L1 cells at 10 uM by oil red o staining-based assay2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.
AID1852831Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1569582Agonist activity at TGR5 in human NCI-H716 cells assessed as increase in cAMP accumulation after 60 mins by HTR-FRET assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1277415Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1609542Upregulation of FXR mRNA expression in human LO2 cells at 80 uM after 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1187925Agonist activity at GAL4 DNA binding domain tagged FXR ligand binding domain (unknown origin) expressed in human HepG2 cells co-expressing human PLTP gene promoter assessed as transactivation of PLTP promoter driven luciferase activity at 10 uM relative t2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Cryptochinones from Cryptocarya chinensis act as farnesoid X receptor agonists.
AID1059679Agonist activity at TGR5 S270A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1351287Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment after 30 mins by Alpha Screen assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1412071Pro-angiogenic activity in HUVEC assessed as decrease in VE-cadherin expression at 12.5 uM after overnight incubation by FITC-conjugated phalloidin staining based confocal microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1412068Increase in MMP9 level in HUVEC at 12.5 uM after 24 hrs by ELISA2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID592920Induction of FXR-mediated BSEP mRNA expression in human HepG2 cells at 20 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1059692Selectivity ratio of EC50 for TGR5 N93A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID297449Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay relative to lithocholic acid2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1138172Agonist activity at FXR in human HepG2 cells assessed as upregulation of BESP mRNA expression at 10 uM after 18 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
AID592918Induction of FXR-mediated SHP mRNA expression in human HepG2 cells at 20 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID409880Cytotoxicity against human HCT116 cells at 50 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1576216Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotinylated SRC-1 recruitment after 30 mins by Alpha Screen assay2019MedChemComm, Aug-01, Volume: 10, Issue:8
Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool.
AID1609588Upregulation of FXR protein expression in human LO2 cells at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1852833Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1232938Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1305701Agonist activity at farnesoid x receptor(unknown origin)2016Bioorganic & medicinal chemistry, Aug-01, Volume: 24, Issue:15
Novel approaches to map small molecule-target interactions.
AID1166210Agonist activity at FXR in human HepG2 cells assessed as induction of IBABP mrNA expression at 50 uM by quantitative PCR method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID714968Agonist activity at human FXR expressed in human HepG2 cells assessed as transactivation of SHP gene by measuring relative luciferase activity by transient transfection reporter assay relative to control2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID679680TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, CDCA: 100 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID1633315Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID1232958Partial agonist activity at FXR in human HepG2 cells assessed as induction of BSEP gene expression at 50 uM after 24 hrs by qRT-PCR analysis (Rvb = 100%)2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1412064Increase in VEGFR1 m-RNA expression in HUVEC at 12.5 uM after 12 to 24 hrs by RT-qPCR analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID303512Activation of TGR5 expressed in HEK293 cells assessed as elevation of cAMP production at 10 uM relative to control2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1609604Increase in FXR protein expression in guggulsterone-treated human LO2 cells at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1609545Agonist activity at FXR in human LO2 cells assessed as increase in UGT2A4 mRNA expression at 80 uM after 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1413747Transactivation of full-length FXR (unknown origin) expressed in HEK293 cells after 18 hrs by dual-glo luciferase reporter gene assay2018MedChemComm, Oct-01, Volume: 9, Issue:10
Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.
AID1609543Agonist activity at FXR in human LO2 cells assessed as increase in SHP1 mRNA expression at 80 uM after 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID662691Enhancement of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 10 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scint2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID681660TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 5 uM, CDCA: 50 uM) in membrane vesicles isolated from Bsep-expressing Balb-3T3 cells2000Gene, Jan-04, Volume: 241, Issue:1
Molecular cloning and characterization of the murine bile salt export pump.
AID422554Agonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to control2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1233568Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 20 ug/ml by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1451548Transactivation of FXR in human HepG2 cells assessed as FGF19 mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID303493Activation of human PXR expressed in HEK293 cells at 50 uM by GAL4 activation assay relative to control2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID657096Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scin2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID714963Agonist activity at human FXR expressed in human HepG2 cells assessed as down-regulation of CYP7A1 gene transactivation at 10 uM by measuring relative luciferase activity by transient transfection reporter assay relative to control2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators.
AID54340Binding constant towards cyclodextrin conjugated peptide (with pyrene) at 25 degrees Centigrade2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Fluorescence resonance energy transfer in a novel cyclodextrin-peptide conjugate for detecting steroid molecules.
AID1233552Cytotoxicity against human WI38 cells by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID672335Agonist activity at FXR LBD expressed in human HepG2 cells co-expressing GAL4 DBD and pG5-luc assessed as SHP promoter-driven luciferase activity at 10 uM after 48 hrs by transient transfection reporter assay relative to control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Triterpenes from Alisma orientalis act as farnesoid X receptor agonists.
AID1138170Agonist activity at FXR in human HepG2 cells assessed as upregulation of SHP mRNA expression at 10 uM after 18 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
AID265705Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
AID592919Induction of FXR-mediated SHP mRNA expression in human HepG2 cells at 1 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1327990Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel 3,4-seco bile acid diamides as selective anticancer proliferation and migration agents.
AID1609590Agonist activity at FXR in human LO2 cells assessed as increase in BSEP protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1686017Agonist activity at TGR5 in human NCI-H716 cells assessed as stimulation of intracellular cAMP accumulation incubated for 60 mins by HTR-FRET assay2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID629056Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity at 10 ug/mL after 18 hrs by dual luciferase reporter gene assay relative to control2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID441576Solubility in 0.1M HCl water solution2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID587932Antagonist activity at FXR expressed in human HepG2 cells assessed as inhibition of CDCA-induced transactivation of FXR at 50 uM after 18 hrs by luminometric analysis2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.
AID303511Activation of IBABP gene expression in human Caco-2 cells at 25 uM after 6 days by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1234671Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes after 12 days by ELISA reader2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Enzymatic synthesis of bile acid derivatives and biological evaluation against Trypanosoma cruzi.
AID592913Agonist activity at human GST-fused FXR LBD assessed as coactivator interaction with receptor ligand binding domain by Alphascreen assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1165599Agonist activity at human FXR ligand binding domain assessed as induction of biotinylated SRC1 peptide recruitment at 4 uM by coactivator recruitment assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
AID1059687Selectivity ratio of EC50 for TGR5 N76A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1187912Agonist activity at GAL4 DNA binding domain tagged FXR ligand binding domain (unknown origin) expressed in human HepG2 cells assessed as receptor transactivation measured by relative luciferase activity at 10 uM by luciferase reporter gene based mammalian2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Cryptochinones from Cryptocarya chinensis act as farnesoid X receptor agonists.
AID1232961Partial agonist activity at FXR in human HepG2 cells assessed as induction of SHP gene expression at 50 uM after 24 hrs by qRT-PCR analysis (Rvb = 100%)2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID680230TP_TRANSPORTER: uptake of Chenodeoxycholate at 20 uM in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID680037TP_TRANSPORTER: inhibition of BSP uptake (BSP: 10 uM, CDCA: 200 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID1124818Activation of FXR (unknown origin) at 10 uM2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Some non-conventional biomolecular targets for diamidines. A short survey.
AID1166192Agonist activity at FXR in human HepG2 cells assessed as induction of CYP7A1 mrNA expression at 50 uM by quantitative PCR method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1686061Drug metabolism in bile of fistula Wistar-Han rat model assessed as area under the curve of the biliary concentration corrected for the bile volume at 60 umol/kg, ID measured at 4 hrs by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID441572Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID303505Activation of SHP gene expression in human HepG2 cells at 25 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1609605Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in SHP1 protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1451551Transactivation of FXR in human HepG2 cells assessed as PDK4 mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1059690Agonist activity at wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID409878Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID680638TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, CDCA: 100 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID1063186Induction of necrosis in human HT1080 cells up to 500 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid.
AID1609593Agonist activity at FXR in human LO2 cells assessed as decrease in CYP7A1 protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1193333Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists.
AID659712Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 5 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID441583Cholerectic effect in bile fistula rat model assessed as maximum bile secretion rate at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1351286Binding affinity to bovine serum albumin at 10 uM after 24 hrs by equilibrium dialysis method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1852829Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID672332Agonist activity at FXR LBD expressed in human HepG2 cells co-expressing GAL4 DBD and pG5-luc assessed as luciferase activity at 10 uM after 48 hrs by transient transfection reporter assay relative to control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Triterpenes from Alisma orientalis act as farnesoid X receptor agonists.
AID72526Effective concentration against Farnesoid X receptor (FXR)2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
AID303496Activity at human VP16-FXR assessed as activation of SRC1 interaction domain 2 recruitment at 50 uM by mammalian two-hybrid assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID388375Agonist activity at FXR assessed as activation by cell based luciferase transactivation assay at 10 uM2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
AID1233559Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1451493Transactivation of FXR in human HepG2 cells assessed as BSEP mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID6737491-Octanol/water partition coefficient, log P of the compound by conventional shake-flask method2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1412050Antiangiogenic activity in HUVEC assessed as inhibition of endothelial tube formation at 25 uM after overnight incubation by inverted microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1059684Agonist activity at TGR5 N93A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1686033Critical micelle concentration in 0.15 M NaCl water solution2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID422555Antagonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to chenodeoxycholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1412053Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as increase in branching of sub-intestinal veins at 12.5 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID294206Inhibition of FXR in HEK293 cells in presence of CDCA at 100 uM by GAL4 transactivation activity2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
AID441581Cholerectic effect in bile fistula rat model assessed as maximum bile secretion rate at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1451530Transactivation of FXR in human HepG2 cells assessed as SHP mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1166204Agonist activity at FXR in human HepG2 cells assessed as induction of BSEP mrNA expression at 50 uM by quantitative PCR method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1059678Agonist activity at TGR5 N76A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID673750Aqueous solubility of the compound in 0.1 M HCl water at pH 3 by HPLC-ES-MS/MS2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1609607Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in MRP2 protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID659715Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 50 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID441580Metabolic stability in bile fistula rat model assessed as conjugated drug level recovered in bile at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1609591Agonist activity at FXR in human LO2 cells assessed as increase in MRP2 protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1609592Agonist activity at FXR in human LO2 cells assessed as increase in SULT2A protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID324925Agonist activity at human FXR expressed in COS1 cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID635574Agonist activity at FXR in human HepG2 cells assessed as decrease in CYP7A1 mRNA expression at 50 uM after 6 hrs by quantitative PCR analysis2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1686052Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum bile secretion at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID673745Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis relative to 10 uM LCA2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1686034Surface tension value in 0.15 M NaCl water solution2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1451541Transactivation of FXR in human HepG2 cells assessed as SREBP1c mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID673751Binding affinity to albumin by equilibrium dialysis2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID409876Cytotoxicity against human GBM cells at 50 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID1609594Agonist activity at FXR in human LO2 cells assessed as decrease in CYP8B1 protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID72525Binding affinity for Farnesoid X Receptor (FXR)2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
AID54341Sensitivity value towards cyclodextrin conjugated peptide (with pyrene) at 25 degrees Centigrade2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Fluorescence resonance energy transfer in a novel cyclodextrin-peptide conjugate for detecting steroid molecules.
AID1852832Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID679790TP_TRANSPORTER: inhibition of Daunomycin uptake in canalicular membrane vesicles1994Hepatology (Baltimore, Md.), Jul, Volume: 20, Issue:1 Pt 1
Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles.
AID672341Agonist activity at FXR LBD expressed in human HepG2 cells co-expressing GAL4 DBD and pG5-luc assessed as PLTP promoter-driven luciferase activity at 10 uM after 48 hrs by transient transfection reporter assay relative to control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Triterpenes from Alisma orientalis act as farnesoid X receptor agonists.
AID1233565Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 100 ug/ml by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID303498Activation of human FXR/RXRalpha heterodimer at 50 uM by FXRE TK-luciferase reporter gene assay relative to control2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1277420Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 18 hrs by CellTiter-Glo luminescence assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID679473TP_TRANSPORTER: Western in vitro, primary human hepatocyte2001The Journal of biological chemistry, Oct-19, Volume: 276, Issue:42
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.
AID388376Agonist activity at FXR assessed as activation by cell based luciferase transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
AID1161667Agonist activity at human GPBAR1 expressed in HEK293T cells assessed as stimulation of cAMP response element-mediated receptor transactivation at 10 uM by luciferase reporter gene assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
AID441578Binding affinity to albumin2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1313848Agonist activity at FXR (unknown origin)2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1063178Induction of necrosis in human Caco2 cells up to 500 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid.
AID629094Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID1609611Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as reduction in NTCP protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1609589Agonist activity at FXR in human LO2 cells assessed as increase in SHP1 protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1412075Increase in wound healing in HUVEC at 12.5 uM after 18 to 24 hrs by phase contrast microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1847971Invivo antagonist activity against FXR in mouse assessed as reduction in Fxr level at 50 uM2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID592923Induction of FXR-mediated Ostbeta mRNA expression in human HepG2 cells at 1 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1412072Pro-angiogenic activity in HUVEC assessed as decrease in cell-to-cell contact at 12.5 uM after overnight incubation by FITC-conjugated phalloidin staining based confocal microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1779666Agonist activity at human BLT2 overexpressed in CHO-K1 cells assessed as accumulation of inositol monophosphate measured after 90 mins by HTRF assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.
AID1412049Induction of angiogenesis in HUVEC assessed as increase in number of nodes at 12.5 uM after overnight incubation by inverted microscopic analysis relative to control2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1609587Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in UGT2A4 mRNA expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1686055Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID240314Effective concentration for recruitment of SRC-1 LxxLL-containing peptide to human Farnesoid X receptor2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Farnesoid X receptor: from structure to potential clinical applications.
AID681332TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID72531Ligand dependent recruitment of SRC1(676-700) peptide to human Farnesoid X-activated receptor by fluorescence resonance energy transfer assay2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Identification of a chemical tool for the orphan nuclear receptor FXR.
AID1233569Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 100 ug/ml by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID673744Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1412060Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as sub-intestinal vein baskets extending towards ventral side at 12.5 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1232963Partial agonist activity at FXR in human HepG2 cells assessed as induction of OST-alpha gene expression at 50 uM after 24 hrs by qRT-PCR analysis (Rvb = 100%)2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID1451554Transactivation of FXR in human HepG2 cells assessed as FABP1 mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID592925Induction of FXR-mediated down-regulation of Cyp7A1 mRNA expression in human HepG2 cells at 20 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1852825Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1686054Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1412065Increase in VEGFR2 m-RNA expression in HUVEC at 12.5 uM after 12 to 24 hrs by RT-qPCR analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID303494Antagonist activity at human FXR expressed in HEK293 cells assessed as inhibition of GW-4064-induced response at 100 uM by GAL4 activation assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID592921Induction of FXR-mediated BSEP mRNA expression in human HepG2 cells at 1 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID592917Agonist activity at human TGR5 receptor expressed in NCI-H716 cells assessed as intracellular cAMP level by TR-FRET assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID587939Activation of FXR expressed in human HepG2 cells assessed as dissociation of NCoR from OSTalpha promoter at 50 uM after 18 hrs by chromatin immunoprecipitation2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.
AID1166198Agonist activity at FXR in human HepG2 cells assessed as induction of OSTalpha mrNA expression at 50 uM by quantitative PCR method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID673748Critical micelle concentration of the compound in 0.15 M NaCl water solution2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1138165Induction of cAMP production in GP-BAR1-deficient HEK293T cells at 10 uM by cAMP responsive element containing luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
AID1327991Antiproliferative activity against human ES2 cells after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel 3,4-seco bile acid diamides as selective anticancer proliferation and migration agents.
AID422543Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.03 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1686015Agonist activity at glutathione transferase-tagged human FXR-LBD using biotinylated Src-1 peptide incubated for 30 mins by recruitment coactivator assay2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID297453Ratio of EC50 for TGR5 expressed in CHO cells to EC50 for FXR expressed in COS1 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1349338Agonist activity at human FXR assessed as recruitment of SRC1 peptide by TR-FRET assay2017ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.
AID1059685Selectivity ratio of EC50 for TGR5 S270A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1686060Drug metabolism in bile of fistula Wistar-Han rat model assessed as area under the curve of the biliary concentration corrected for the bile volume at 60 umol/kg, iv measured at 4 hrs by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID303504Activation of SHP gene expression in human Huh7 cells at 20 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1059689Selectivity ratio of EC50 for TGR5 E169A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1412054Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as increase in sprouting and branching of sub-intestinal vessels (after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1609595Agonist activity at FXR in human LO2 cells assessed as decrease in NTCP protein expression at 80 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID409890Cytotoxicity against human HCT116 cells at 25 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID1161670Antagonist activity against FXR (unknown origin) expressed in human HepG2 cells assessed as inhibition of CDCA-induced stimulation of FXR response element IR1-mediated receptor transactivation at 50 uM by luciferase reporter gene assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
AID1569579Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay relative to control2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.
AID702678Agonist activity at GST tagged human recombinant FXRalphaLBD expressed in Escherichia coli BL21 cells assessed as SRC-1 co-activator association after 30 mins by HTRF assay2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
AID1412074Induction of angiogenesis in HUVEC assessed as increase in tube length at 12.5 uM after overnight incubation by inverted microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID297450Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1166181Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID409891Cytotoxicity against human KMS11 cells at 25 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID672338Agonist activity at FXR LBD expressed in human HepG2 cells co-expressing GAL4 DBD and pG5-luc assessed as transrepression of rat CYP7A1 promoter-driven luciferase activity at 10 uM after 48 hrs by transient transfection reporter assay relative to control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Triterpenes from Alisma orientalis act as farnesoid X receptor agonists.
AID1442220Binding affinity to FXR-LBD (unknown origin) assessed as melting temperature at 200 mM by CD spectroscopic method (Rvb = 46 +/- 0.1 degC)2017European journal of medicinal chemistry, Mar-31, Volume: 129Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists.
AID72530Farnesoid X-activated receptor activity compared to 50 uM chenodeoxycholic acid (CDCA)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Identification of a chemical tool for the orphan nuclear receptor FXR.
AID441585Metabolic stability in bile fistula rat model assessed as intact drug level recovered in bile at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1232965Partial agonist activity at FXR in human HT-29 cells assessed as induction of IBABP gene expression at 50 uM after 24 hrs by qRT-PCR analysis (Rvb = 100%)2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID660288Induction of apoptosis in human multinucleated osteoclasts obtained from PBMC assessed as formation of apoptotic nuclear bodies at 10'-5 M after 7 days by Hoechst 33258 staining2012European journal of medicinal chemistry, Jun, Volume: 52Synthesis, characterization and biological activity of hydroxyl-bisphosphonic analogs of bile acids.
AID1546885Agonist activity at FXR (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1412052Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as increase in sprouting of sub-intestinal veins at 12.5 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID409883Cytotoxicity against human HCT116 cells at 50 uM after 48 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID1446797Agonist activity at FXR (unknown origin) assessed as recruitment of SRC1 peptide to FXR by FRET assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
AID680004TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, CDCA: 200 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID16860351-octanol-water partition coefficient, logP of compound as ionized species2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1686058Drug metabolism in bile of fistula Wistar-Han rat model assessed as taurine conjugate formation at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1277417Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1686036Binding affinity to human serum albumin2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID269847Agonist activity at FXR in HepG2 cells by luciferase activity relative to DMSO at 10 uM2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
AID1351284Octanol-phosphate buffer distribution coefficient, log P of the compound at pH 7.4 at 1 uM after 24 hrs by shake flask method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID1852828Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID303492Activation of human PXR expressed in HEK293 cells at 20 uM by GAL4 activation assay relative to control2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1412040Toxicity in zebrafish embryo assessed as reduction in embryo survival up to 50 uM2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1443906Antibacterial activity against Clostridium difficile NAP1 assessed as concentration required for complete inhibition of TCA-induced spore germination measured after 20 mins under anaerobic condition2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination.
AID1059686Selectivity ratio of EC50 for TGR5 Y89F mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1327989Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel 3,4-seco bile acid diamides as selective anticancer proliferation and migration agents.
AID1633314Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment at 5 uM after 30 mins by Alpha Screen assay relative to 6-ECDCA2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1451534Transactivation of FXR in human HepG2 cells assessed as CYP7A1 mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1609609Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as reduction in CYP7A1 protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID490122Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID659713Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 10 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID662693Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay relative to GW40642012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID1569580Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.
AID592924Induction of FXR-mediated down-regulation of Cyp7A1 mRNA expression in human HepG2 cells at 1 uM by RT-PCR2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
AID1569578Cytotoxicity against CHO cells expressing human TGR5 at 30 to 100 uM2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.
AID1063187Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid.
AID409881Cytotoxicity against human KMS11 cells at 50 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID1458345Lipophilicity, logD of compound at pH 7.4 by LC-MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Nonacidic Farnesoid X Receptor Modulators.
AID297452Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay relative to 6ECDCA2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID297451Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1351283Solubility of the compound in pH 1 HCl solution at 300 uM after 24 hrs by HPLC-ESI-MS analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID659710Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 0.1 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID490121Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID267784Binding affinity to FXR assessed as ligand-dependent SRC1 recruitment by FRET based co-activator assay2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
AID1686032Solubility in water measured for protonated species2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1412070Pro-angiogenic activity in HUVEC assessed as stress fiber formation at 12.5 uM after overnight incubation by FITC-conjugated phalloidin staining based confocal microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID324926Agonist activity against human FXR expressed in COS1 cells by luciferase assay relative to 6-enantiomeric chenodeoxy cholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1609606Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in BSEP protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID587931Agonist activity at FXR expressed in human HepG2 cells assessed as beta-galactosidase activity at 10 uM after 18 hrs by luminometric analysis2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.
AID682019TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.72 uM, CDCA: 72 uM) in Ntcp-expressing COS-7 cells2002Bioscience, biotechnology, and biochemistry, May, Volume: 66, Issue:5
Characterization of cloned mouse Na+/taurocholate cotransporting polypeptide by transient expression in COS-7 cells.
AID1412059Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as arcades formation at 12.5 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1719697Agonist activity at FXR in human HepG2 cells assessed as increase in BSEP mRNA expression at 30 uM incubated for 8 hrs by qRT-PCR analysis2021ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
A New FXR Ligand Chemotype with Agonist/Antagonist Switch.
AID1686057Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion of the administered compound including the secreted taurine conjugates at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID629057Agonist activity at FXR in human HepG2 cells assessed as inhibition of CYP7A1 mRNA expression at 50 uM for 6 hrs by RT-PCR relative to control2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID681352TP_TRANSPORTER: transepithelial transport (basal to apical) in Ntcp/Bsep double transfected MDCK cell2005American journal of physiology. Gastrointestinal and liver physiology, Jan, Volume: 288, Issue:1
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.
AID303508Decrease in CYP7A1 gene expression in human HepG2 cells at 25 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID303500Activation of BSEP gene expression in human Huh7 cells at 20 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1686053Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum bile secretion at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1277414Antagonist activity against VDR-LBD (unknown origin) expressed in Escherichia coli assessed as inhibition of VDR agonist LG190178-induced SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID441584Cholerectic effect in bile fistula rat model assessed as maximum bile acids secretion rate per kg body weight at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID409877Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID324927Selectivity index, ratio of EC50 for human TGR5 to EC50 for human FXR2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1233567Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 100 ug/ml by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1412073Cytotoxicity against HUVEC assessed as reduction in cell viability at 6.25 to 100 uM after 24 hrs by MTT assay2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1852827Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1609585Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in SHP1 mRNA expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1063189Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid.
AID1165586Agonist activity at FXR (unknown origin) expressed in human HepG2 cells assessed as receptor transactivation at 10 uM incubated for 16 hrs by FXR response element driven HSP27-TK-luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
AID1412069Decrease in MMP9 level in HUVEC at 12.5 uM after 24 hrs by ELISA2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID645565Agonist activity at FXR in human HepG2 cells at 10 uM after 48 hrs by luciferase reporter gene based transactivation assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID409889Cytotoxicity against human GBM cells at 25 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID1166182Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay relative to 3 uM GW40642014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1451544Transactivation of FXR in human HepG2 cells assessed as FAS mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1609544Agonist activity at FXR in human LO2 cells assessed as increase in BSEP mRNA expression at 80 uM after 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID422556Enhancement of bile salt export pump promoter transactivation2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID673746Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1811597Inhibition of Taurocholate-induced spore germination in Clostridioides difficile UK1 at 100 mM by spectrophotometric method2021Bioorganic & medicinal chemistry, 12-15, Volume: 52Studies on the Importance of the 7α-, and 12α- hydroxyl groups of N-Aryl-3α,7α,12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID629055Agonist activity at FXR2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID1351282Solubility of the compound in pH 7.4 PBS buffer at 300 uM after 24 hrs by HPLC-ESI-MS analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID659711Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 1 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID72527Relative recruitment of SRC1 peptide to Farnesoid X receptor (FXR) where CDCA=100%2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
AID441582Cholerectic effect in bile fistula rat model assessed as maximum bile acids secretion rate per kg body weight at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID422544Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.007 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1412043Cytotoxicity against HUVEC assessed as reduction in cell death up to 12.5 uM after 24 hrs by MTT assay2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1451537Transactivation of FXR in human HepG2 cells assessed as PPARalpha mRNA expression at 50 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1351285Octanol-HCl distribution coefficient, log P of the compound at pH 1 at 1 uM after 24 hrs by shake flask method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID409884Cytotoxicity against human KMS11 cells at 50 uM after 48 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID1277413Agonist activity at VDR-LBD (unknown origin) expressed in Escherichia coli assessed as SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1719696Agonist activity at FXR in human HepG2 cells assessed as increase in SHP mRNA expression at 30 uM incubated for 8 hrs by qRT-PCR analysis2021ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
A New FXR Ligand Chemotype with Agonist/Antagonist Switch.
AID409879Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID441577Critical micellar concentration in 0.15 M NaCl water solution2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1232939Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay relative to 3 uM GW40642015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1609610Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as reduction in CYP8B1 protein expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1412076Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo at 6.25 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1686018Agonist activity at TGR5 in human NCI-H716 cells assessed as stimulation of intracellular cAMP accumulation incubated for 60 mins by HTR-FRET assay relative to 10 uM LCA2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1187920Agonist activity at GAL4 DNA binding domain tagged FXR ligand binding domain (unknown origin) expressed in human HepG2 cells co-expressing rat CYP7A1 gene promoter assessed as transrepression of CYP7A1 promoter driven luciferase activity at 10 uM2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Cryptochinones from Cryptocarya chinensis act as farnesoid X receptor agonists.
AID635573Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID662692Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID441579Metabolic stability in bile fistula rat model assessed as intact drug level recovered in bile at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID490123Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID1847972Invivo antagonist activity against FXR in mouse assessed as reduction in Fgf15 level at 50 uM2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID679670TP_TRANSPORTER: Northern blot from HepG2 cells2002The Journal of biological chemistry, Jan-25, Volume: 277, Issue:4
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.
AID1609586Agonist activity at FXR in guggulsterone-treated human LO2 cells assessed as increase in BSEP mRNA expression at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1234672Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes at 300 uM after 12 days by ELISA reader2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Enzymatic synthesis of bile acid derivatives and biological evaluation against Trypanosoma cruzi.
AID1138171Agonist activity at FXR in human HepG2 cells assessed as upregulation of OST-alpha mRNA expression at 10 uM after 18 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
AID659714Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 25 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID422553Binding affinity to pig PLA2 at 100 uM by saturation transfer difference NMR spectroscopy2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID657097Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 10 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scint2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID659716Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 100 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID660287Inhibition of osteoclastogenesis in human osteoclasts obtained from PBMC assessed as formation of TRAPC positive multinucleated cells at 10'-5 M after 7 days2012European journal of medicinal chemistry, Jun, Volume: 52Synthesis, characterization and biological activity of hydroxyl-bisphosphonic analogs of bile acids.
AID682147TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 5 uM, CDCA: 100 uM) in Ntcp-expressing COS-7 cells1994The American journal of physiology, Mar, Volume: 266, Issue:3 Pt 1
Expression and characterization of a functional rat liver Na+ bile acid cotransport system in COS-7 cells.
AID1609584Increase in FXR mRNA expression in guggulsterone-treated human LO2 cells at 80 uM treated with FXR antagonist, guggulsterone for 24 hrs followed by incubation with compound for 24 hrs by RT-qPCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID679712TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.72 uM, CDCA: a 100-fold excess) in isolated mouse ileocytes1999Journal of biochemistry, Apr, Volume: 125, Issue:4
Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter.
AID243397Efficacy for human Farnesoid X receptor in FRET assay2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
AID1233553Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1799080HTRF Coactivator Recruitment Assay from Article 10.1073/pnas.0710981105: \\Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.\\2008Proceedings of the National Academy of Sciences of the United States of America, Apr-08, Volume: 105, Issue:14
Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.
AID1798108TGR5 Activity Assay from Article 10.1021/jm070633p: \\Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.\\2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1798109FXR Activity Assay from Article 10.1021/jm070633p: \\Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.\\2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1798115Cotransfection Assay from Article 10.1016/j.bmc.2007.01.046: \\Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.\\2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,200)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901604 (50.13)18.7374
1990's460 (14.38)18.2507
2000's345 (10.78)29.6817
2010's582 (18.19)24.3611
2020's209 (6.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.59 (24.57)
Research Supply Index8.18 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index86.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials227 (6.79%)5.53%
Reviews304 (9.09%)6.00%
Case Studies151 (4.52%)4.05%
Observational7 (0.21%)0.25%
Other2,654 (79.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of the Effects of Obeticholic Acid on Farnesoid X Receptor Expression in Jejunum and on Gut Microbiota in Morbidly Obese Patients and Healthy Volunteers [NCT02532335]Phase 140 participants (Anticipated)Interventional2015-08-31Recruiting
Effect of Obeticholic Acid (INT-747, Intercept) on the Hepatobiliary Transport of Bile Acids in Patients With PBC Examined by 11C-cholyl-sarcosine PET/CT [NCT03253276]Early Phase 18 participants (Actual)Interventional2016-05-19Completed
A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis [NCT04270682]Phase 318 participants (Actual)Interventional2020-01-31Completed
Obeticholic Acid Treatment in Patients With Bile Acid Diarrhoea: an Open-label, Pilot Study of Mechanisms, Safety and Symptom Response. [NCT01585025]Phase 235 participants (Actual)Interventional2012-04-30Completed
Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 [NCT02314208]Phase 212 participants (Actual)Interventional2015-01-31Completed
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy [NCT03168555]Phase 423 participants (Actual)Interventional2017-06-22Completed
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis [NCT05239468]Phase 260 participants (Anticipated)Interventional2022-03-21Active, not recruiting
Retrospective Cohort Study to Investigate the Safety and Efficacy of Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX) [NCT05499026]28 participants (Actual)Observational2014-12-09Completed
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients [NCT02430077]Phase 210 participants (Actual)Interventional2016-06-30Completed
A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary Atresia [NCT05321524]Phase 27 participants (Actual)Interventional2015-07-01Terminated(stopped due to After extensive efforts to improve recruitment, it is deemed not feasible to enroll the requisite number of subjects to generate data needed to meet the study objectives. EMA Paediatric Committee agreed with the Sponsor to terminate this study.)
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) [Dose: 1 x 02 Capsules] Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250m [NCT06180057]Phase 124 participants (Actual)Interventional2022-06-12Completed
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NCT03439254]Phase 3919 participants (Actual)Interventional2017-08-30Completed
An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA) [NCT01904539]Phase 132 participants (Actual)Interventional2013-06-30Completed
An Open Label Trial to Assess the Effects of Food on the Pharmacokinetic Parameters of Obeticholic Acid (OCA) [NCT01914562]Phase 132 participants (Actual)Interventional2013-08-31Completed
An Open Label, Randomized, Single Dose and Multiple Dose Trial to Assess the Pharmacokinetics of Obeticholic Acid (OCA) [NCT01933503]Phase 124 participants (Actual)Interventional2013-10-31Completed
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial [NCT01265498]Phase 2283 participants (Actual)Interventional2011-03-31Completed
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis [NCT00570765]Phase 260 participants (Actual)Interventional2008-01-17Completed
Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass [NCT02876484]Phase 412 participants (Actual)Interventional2016-06-30Completed
A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis [NCT01473524]Phase 3217 participants (Actual)Interventional2012-01-31Completed
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass [NCT02952963]Phase 48 participants (Actual)Interventional2016-10-31Completed
Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia [NCT00465751]Early Phase 130 participants (Actual)Interventional2004-10-31Completed
Biologic Significance of Cholestanol in Man [NCT00018694]0 participants (Actual)Interventional1999-10-31Withdrawn
Effect of Chenodeoxycholic Acid on Gastrointestinal Transit and Colonic Functions in Health and Constipation-predominant Irritable Bowel Syndrome (IBS-C) [NCT00912301]Phase 236 participants (Actual)Interventional2009-04-30Completed
Effects of Obeticholic Acid on Hepatic Fatty Acid/Triglyceride Metabolism and Hepatobiliary Detoxification/Elimination in Morbidly Obese and Gallstone Patients [NCT01625026]Phase 240 participants (Actual)Interventional2013-09-30Completed
Effect of Bile Acids in the Gut on GLP-1 Secretion in Healthy Subjects and Patients With Type 2 Diabetes [NCT01666223]20 participants (Actual)Interventional2012-11-30Completed
Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis [NCT05293938]0 participants (Actual)Observational2022-03-28Withdrawn(stopped due to A fundamental protocol deviation on data capture left the database no longer fit for purpose.)
Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX) [NCT00004346]Phase 25 participants Interventional1996-01-31Recruiting
[NCT00004442]25 participants (Anticipated)InterventionalTerminated
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis [NCT01865812]Phase 227 participants (Actual)Interventional2013-12-03Completed
Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on GLP-1 Secretion After Roux-en-Y Gastric Bypass [NCT02340247]Phase 411 participants (Actual)Interventional2014-11-30Completed
Effect of Intraduodenal Perfusion of Bile Acids on the Secretion of Gastrointestinal Satiation Peptides in Healthy Male Volunteers [NCT01674946]Phase 112 participants (Actual)Interventional2011-09-30Completed
Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea [NCT03059537]Phase 471 participants (Actual)Interventional2017-03-13Completed
Replicate Studies Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis [NCT05292872]4,937 participants (Actual)Observational2022-03-28Completed
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition [NCT04640571]Phase 418 participants (Actual)Interventional2021-04-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00570765 (14) [back to overview]LTSE: Mean Percent Change In GGT From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE Phase: Median Percent Change In Serum ALP From Baseline To Month 24, Month 48, Month 72, And Last Available Visit
NCT00570765 (14) [back to overview]LTSE Phase: Mean Percent Change In Serum ALP From Baseline To Month 24, Month 48, Month 72, And Last Available Visit
NCT00570765 (14) [back to overview]DB Phase: Mean Percent Change In Alanine Transaminase (ALT) From Baseline To Day 85
NCT00570765 (14) [back to overview]DB Phase: Mean Percent Change In Conjugated Bilirubin From Baseline To Day 85
NCT00570765 (14) [back to overview]DB Phase: Mean Percent Change In Gamma-glutamyl Transferase (GGT) From Baseline To Day 85
NCT00570765 (14) [back to overview]DB Phase: Mean Percent Change In Serum Alkaline Phosphatase (ALP) From Baseline To Day 85
NCT00570765 (14) [back to overview]LTSE: Mean Percent Change In ALT From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE: Mean Percent Change In Conjugated Bilirubin From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE: Mean Percent Change In Total Bilirubin From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE: Median Percent Change In ALT From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE: Median Percent Change In Conjugated Bilirubin From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE: Median Percent Change In GGT From Baseline To Last Available Visit
NCT00570765 (14) [back to overview]LTSE: Median Percent Change In Total Bilirubin From Baseline To Last Available Visit
NCT00912301 (5) [back to overview]Colonic Filling at 6 Hours
NCT00912301 (5) [back to overview]Ascending Colon Emptying (AC t_1/2)
NCT00912301 (5) [back to overview]Stool Consistency
NCT00912301 (5) [back to overview]Colonic Transit at 48 Hours (GC48)
NCT00912301 (5) [back to overview]Colonic Geometric Center at 24 Hours (GC24)
NCT01265498 (48) [back to overview]Steatosis: Change in Score
NCT01265498 (48) [back to overview]Steatosis: Patients With Improvement
NCT01265498 (48) [back to overview]Total NAFLD Activity Score: Change in Score
NCT01265498 (48) [back to overview]Change in Haematocrit
NCT01265498 (48) [back to overview]Change in γ-glutamyl Transpeptidase
NCT01265498 (48) [back to overview]Fibrosis: Change in Score
NCT01265498 (48) [back to overview]Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)
NCT01265498 (48) [back to overview]Fibrosis: Patient With Improvement
NCT01265498 (48) [back to overview]Hepatocellular Ballooning: Change in Score
NCT01265498 (48) [back to overview]Hepatocellular Ballooning: Patients With Improvement
NCT01265498 (48) [back to overview]Lobular Inflammation: Change in Score
NCT01265498 (48) [back to overview]Lobular Inflammation: Patients With Improvement
NCT01265498 (48) [back to overview]Portal Inflammation: Change in Score
NCT01265498 (48) [back to overview]Change in Body-mass Index
NCT01265498 (48) [back to overview]Portal Inflammation: Patients With Improvement
NCT01265498 (48) [back to overview]Resolution of NASH Diagnosis
NCT01265498 (48) [back to overview]Change in Alanine Aminotransferase
NCT01265498 (48) [back to overview]Change in Albumin
NCT01265498 (48) [back to overview]Change in Alkaline Phosphatase
NCT01265498 (48) [back to overview]Change in Asparate Aminotransferase
NCT01265498 (48) [back to overview]Change in Bicarbonate
NCT01265498 (48) [back to overview]Change in Insulin
NCT01265498 (48) [back to overview]Change in Calcium
NCT01265498 (48) [back to overview]Change in Creatinine
NCT01265498 (48) [back to overview]Change in Diastolic Blood Pressure
NCT01265498 (48) [back to overview]Change in Fasting Serum Glucose
NCT01265498 (48) [back to overview]Change in Glycated Haemoglobin A1c
NCT01265498 (48) [back to overview]Change in Haemoglobin
NCT01265498 (48) [back to overview]Change in HDL Cholesterol
NCT01265498 (48) [back to overview]Change in HOMA-IR
NCT01265498 (48) [back to overview]Change in International Normalised Ratio
NCT01265498 (48) [back to overview]Change in LDL Cholesterol
NCT01265498 (48) [back to overview]Change in Mean Corpuscular Volume
NCT01265498 (48) [back to overview]Change in Phosphate
NCT01265498 (48) [back to overview]Change in Platelet Count
NCT01265498 (48) [back to overview]Change in Prothrombin Time
NCT01265498 (48) [back to overview]Change in SF-36 Quality of Life Mental Component Summary
NCT01265498 (48) [back to overview]Change in SF-36 Quality of Life Physical Component Summary
NCT01265498 (48) [back to overview]Change in Systolic Blood Pressure
NCT01265498 (48) [back to overview]Change in Total Bilirubin
NCT01265498 (48) [back to overview]Change in Total Cholesterol
NCT01265498 (48) [back to overview]Change in Total Protein
NCT01265498 (48) [back to overview]Change in Triglycerides
NCT01265498 (48) [back to overview]Change in Uric Acid
NCT01265498 (48) [back to overview]Change in Waist Circumference
NCT01265498 (48) [back to overview]Change in Waist-to-hip Ratio
NCT01265498 (48) [back to overview]Change in Weight
NCT01265498 (48) [back to overview]Change in White Blood Cell Count
NCT01473524 (13) [back to overview]LTSE Phase: Composite Endpoint ALP And Total Bilirubin
NCT01473524 (13) [back to overview]LTSE Phase: ALP Levels
NCT01473524 (13) [back to overview]LTSE Phase: ALP Change From DB Baseline
NCT01473524 (13) [back to overview]DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12
NCT01473524 (13) [back to overview]DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12
NCT01473524 (13) [back to overview]DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12
NCT01473524 (13) [back to overview]DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo
NCT01473524 (13) [back to overview]DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo
NCT01473524 (13) [back to overview]DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo
NCT01473524 (13) [back to overview]DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12
NCT01473524 (13) [back to overview]DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12
NCT01473524 (13) [back to overview]DB Phase: ALP Absolute Change From Baseline To Month 12
NCT01473524 (13) [back to overview]DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo
NCT01585025 (7) [back to overview]Changes in Fasting 7α-hydroxy-4-cholesten-3-one
NCT01585025 (7) [back to overview]Changes in Fasting FGF19
NCT01585025 (7) [back to overview]Changes in Mean Stool Form
NCT01585025 (7) [back to overview]Changes in Non-fasting Response of FGF19 to OCA
NCT01585025 (7) [back to overview]Changes in Serum Total Bile Acids.
NCT01585025 (7) [back to overview]Changes in Stool Frequency
NCT01585025 (7) [back to overview]Change in Stool Index
NCT01865812 (76) [back to overview]Median Change From Baseline In Macrophage Cholesterol Efflux
NCT01865812 (76) [back to overview]Median Change From Baseline In Prebeta-1 HDL Concentration
NCT01865812 (76) [back to overview]Median Change From Baseline In Prebeta-1 HDL Concentration
NCT01865812 (76) [back to overview]Median Change From Baseline In Prothrombin International Normalized Ratio
NCT01865812 (76) [back to overview]Median Change From Baseline In Prothrombin Time
NCT01865812 (76) [back to overview]Median Change From Baseline In Tissue Inhibitor Of Metalloproteinases 1
NCT01865812 (76) [back to overview]Median Change From Baseline In Total And Unconjugated (Direct) Bilirubin
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Bile Acids
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Chenodeoxycholic Acid
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Cholesterol
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Cholesterol
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Cholic Acid
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Deoxycholic Acid
NCT01865812 (76) [back to overview]Median Change From Baseline In C-reactive Protein
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Endogenous Bile Acid
NCT01865812 (76) [back to overview]Median Change From Baseline In Total LDL Particles
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Lithocholic Acid
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Triglycerides
NCT01865812 (76) [back to overview]Median Change From Baseline In Total Triglycerides
NCT01865812 (76) [back to overview]Median Change From Baseline In Total UDCA
NCT01865812 (76) [back to overview]Median Change From Baseline In Very Low-density Lipoprotein (VLDL) Cholesterol
NCT01865812 (76) [back to overview]Median Change From Baseline In Very Low-density Lipoprotein (VLDL) Cholesterol
NCT01865812 (76) [back to overview]Median Change From Baseline In VLDL Particle Size
NCT01865812 (76) [back to overview]Median Change From Baseline In VLDL Particle Size
NCT01865812 (76) [back to overview]Median Change From Baseline In VLDL Particles
NCT01865812 (76) [back to overview]Median Change From Baseline In VLDL Particles
NCT01865812 (76) [back to overview]Participants With Lipoprotein X
NCT01865812 (76) [back to overview]Time To Reach Cmax (Tmax) For OCA And Conjugates
NCT01865812 (76) [back to overview]Absolute Change From Baseline In HDL Cholesterol Concentration
NCT01865812 (76) [back to overview]Absolute Change From Baseline In HDL Particle Number
NCT01865812 (76) [back to overview]Absolute Change From Baseline In HDL Particle Number
NCT01865812 (76) [back to overview]Absolute Change From Baseline In HDL Particle Size
NCT01865812 (76) [back to overview]Absolute Change From Baseline In HDL Particle Size
NCT01865812 (76) [back to overview]Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration
NCT01865812 (76) [back to overview]Median Change From Week 8 In HDL Cholesterol Concentration At Week 12
NCT01865812 (76) [back to overview]Median Change From Week 8 In HDL Particle Number At Week 12
NCT01865812 (76) [back to overview]Median Change From Week 8 In HDL Particle Size At Week 12
NCT01865812 (76) [back to overview]Area Under The Concentration-time Curve From Hour 0 To Last Sampling Time (Hour 6) (AUC0-6) For OCA And Conjugates
NCT01865812 (76) [back to overview]Maximum Plasma Concentration (Cmax) Of OCA And Conjugates
NCT01865812 (76) [back to overview]Median Change From Baseline In Alanine Aminotransferase
NCT01865812 (76) [back to overview]Median Change From Baseline In Albumin
NCT01865812 (76) [back to overview]Median Change From Baseline In Alkaline Phosphatase
NCT01865812 (76) [back to overview]Median Change From Baseline In Amino-terminal Propeptide Of Type III Procollagen
NCT01865812 (76) [back to overview]Median Change From Baseline In ApoA1/ApoB Ratio
NCT01865812 (76) [back to overview]Median Change From Baseline In ApoA1/ApoB Ratio
NCT01865812 (76) [back to overview]Median Change From Baseline In Apolipoprotein A1 (ApoA1)
NCT01865812 (76) [back to overview]Median Change From Baseline In Apolipoprotein A1 (ApoA1)
NCT01865812 (76) [back to overview]Median Change From Baseline In Apolipoprotein B (ApoB)
NCT01865812 (76) [back to overview]Median Change From Baseline In Apolipoprotein B (ApoB)
NCT01865812 (76) [back to overview]Median Change From Baseline In Apolipoprotein E
NCT01865812 (76) [back to overview]Median Change From Baseline In Apolipoprotein E
NCT01865812 (76) [back to overview]Median Change From Baseline In Aspartate Aminotransferase
NCT01865812 (76) [back to overview]Median Change From Baseline In Total LDL Particles
NCT01865812 (76) [back to overview]Median Change From Baseline In C-reactive Protein
NCT01865812 (76) [back to overview]Median Change From Baseline In Cholesteryl Ester Transfer Protein
NCT01865812 (76) [back to overview]Median Change From Baseline In Cholesteryl Ester Transfer Protein
NCT01865812 (76) [back to overview]Median Change From Baseline In Enhanced Liver Fibrosis (ELF) Score
NCT01865812 (76) [back to overview]Median Change From Baseline In Fibroblast Growth Factor-19
NCT01865812 (76) [back to overview]Median Change From Baseline In Fibroblast Growth Factor-19
NCT01865812 (76) [back to overview]Median Change From Baseline In Gamma-glutamyl Transferase
NCT01865812 (76) [back to overview]Median Change From Baseline In Glycoprotein A
NCT01865812 (76) [back to overview]Median Change From Baseline In Glycoprotein A
NCT01865812 (76) [back to overview]Median Change From Baseline In HDL Cholesterol Concentration At Weeks 4, 8, and 12
NCT01865812 (76) [back to overview]Median Change From Baseline In HDL Particle Number At Weeks 4, 8, and 12
NCT01865812 (76) [back to overview]Median Change From Baseline In HDL Particle Size At Weeks 4, 8, and 12
NCT01865812 (76) [back to overview]Median Change From Baseline In Hepatic Stiffness
NCT01865812 (76) [back to overview]Median Change From Baseline In Hyaluronic Acid
NCT01865812 (76) [back to overview]Median Change From Baseline In LDL Particle Size
NCT01865812 (76) [back to overview]Median Change From Baseline In LDL Particle Size
NCT01865812 (76) [back to overview]Median Change From Baseline In Lecithin-cholesterol Acyltransferase Activity
NCT01865812 (76) [back to overview]Median Change From Baseline In Lecithin-cholesterol Acyltransferase Activity
NCT01865812 (76) [back to overview]Median Change From Baseline In Lipoprotein-a
NCT01865812 (76) [back to overview]Median Change From Baseline In Lipoprotein-a
NCT01865812 (76) [back to overview]Median Change From Baseline In Low-density Lipoprotein (LDL) Cholesterol (Direct)
NCT01865812 (76) [back to overview]Median Change From Baseline In Low-density Lipoprotein (LDL) Cholesterol (Direct)
NCT01865812 (76) [back to overview]Median Change From Baseline In Macrophage Cholesterol Efflux
NCT02430077 (5) [back to overview]Change in the Liver Triglycerides (TG).
NCT02430077 (5) [back to overview]Change in Serum Triglyceride Levels
NCT02430077 (5) [back to overview]Change in Serum Levels of Gamma-Glutamyl Transpeptidase
NCT02430077 (5) [back to overview]Change in Serum Levels of Aspartate Aminotransferases
NCT02430077 (5) [back to overview]Change in Serum Levels of Alanine Aminotransferase
NCT03168555 (11) [back to overview]Change in C4 Total Area Under the Curve From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Chenodeoxycholic Acid (CDCA) Absorption to Plasma From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Fasting 7-alpha-hydroxy-cholestenone (C4) From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Fasting FGF19 From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Lipid Status From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Patient Reported Diarrhea Symptoms Correlated With Change in C4 From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Patient Reported Diarrhea Symptoms Correlated With Change in FGF19 From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy
NCT03168555 (11) [back to overview]Change in Stool Consistency (Bristol Stool Type) From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Stool Frequency From Baseline Before Versus After Cholecystectomy
NCT03168555 (11) [back to overview]Change in Stool Pattern Correlated to FGF19
NCT03439254 (12) [back to overview]DB Phase: Change From Baseline to Month 18 in LSM
NCT03439254 (12) [back to overview]OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03439254 (12) [back to overview]OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death
NCT03439254 (12) [back to overview]OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score
NCT03439254 (12) [back to overview]OLE Phase: Number of Participants Reporting All-cause Mortality
NCT03439254 (12) [back to overview]OLE Phase: Fibrosis-4 (FIB-4) at Baseline
NCT03439254 (12) [back to overview]OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline
NCT03439254 (12) [back to overview]OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)
NCT03439254 (12) [back to overview]DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)
NCT03439254 (12) [back to overview]DB Phase: FIB-4 at Baseline
NCT03439254 (12) [back to overview]DB Phase: ELF at Baseline
NCT03439254 (12) [back to overview]OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15

LTSE: Mean Percent Change In GGT From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in GGT from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Mean)
LTSE OCA Total-55.6

[back to top]

LTSE Phase: Median Percent Change In Serum ALP From Baseline To Month 24, Month 48, Month 72, And Last Available Visit

The percent change in serum ALP from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Month 24, Month 48, Month 72, Last Available Visit (up to 96 months)

InterventionPercent Change (Median)
Month 24Month 48Month 72Last Available Visit
LTSE OCA Total-43.1-44.4-33.4-31.8

[back to top]

LTSE Phase: Mean Percent Change In Serum ALP From Baseline To Month 24, Month 48, Month 72, And Last Available Visit

The percent change in serum ALP from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Month 24, Month 48, Month 72, Last Available Visit (up to 96 months)

InterventionPercent Change (Mean)
Month 24Month 48Month 72Last Available Visit
LTSE OCA Total-38.8-39.3-31.7-30.4

[back to top]

DB Phase: Mean Percent Change In Alanine Transaminase (ALT) From Baseline To Day 85

As a marker of hepatocellular injury and liver function, the percent change in ALT from baseline to Day 85 is reported. (NCT00570765)
Timeframe: Baseline, Day 85

InterventionPercent change (Mean)
DB OCA 10 mg-37
DB OCA 50 mg-35
DB OCA Placebo-4

[back to top]

DB Phase: Mean Percent Change In Conjugated Bilirubin From Baseline To Day 85

As a marker of hepatocellular injury and liver function, the percent change in conjugated bilirubin from baseline to Day 85 is reported. (NCT00570765)
Timeframe: Baseline, Day 85

InterventionPercent Change (Mean)
DB OCA 10 mg0.7
DB OCA 50 mg-1.7
DB OCA Placebo30.3

[back to top]

DB Phase: Mean Percent Change In Gamma-glutamyl Transferase (GGT) From Baseline To Day 85

As a marker of hepatocellular injury and liver function, the percent change in GGT from baseline to Day 85 is reported. (NCT00570765)
Timeframe: Baseline, Day 85

InterventionPercent change (Mean)
DB OCA 10 mg-73
DB OCA 50 mg-65
DB OCA Placebo-3

[back to top]

DB Phase: Mean Percent Change In Serum Alkaline Phosphatase (ALP) From Baseline To Day 85

The percent change in serum ALP from baseline to Day 85 is reported. The baseline value used was the mean of the pretreatment Screening and Day 0 evaluations. (NCT00570765)
Timeframe: Baseline, Day 85

InterventionPercent change (Mean)
DB OCA 10 mg-44.5
DB OCA 50 mg-37.6
DB OCA Placebo0.4

[back to top]

LTSE: Mean Percent Change In ALT From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in ALT from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Mean)
LTSE OCA Total-39.6

[back to top]

LTSE: Mean Percent Change In Conjugated Bilirubin From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in conjugated bilirubin from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Mean)
LTSE OCA Total57.8

[back to top]

LTSE: Mean Percent Change In Total Bilirubin From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in total bilirubin from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Mean)
LTSE OCA Total2.2

[back to top]

LTSE: Median Percent Change In ALT From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in ALT from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Median)
LTSE OCA Total-52.2

[back to top]

LTSE: Median Percent Change In Conjugated Bilirubin From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in conjugated bilirubin from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Median)
LTSE OCA Total33.3

[back to top]

LTSE: Median Percent Change In GGT From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in GGT from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Median)
LTSE OCA Total-71.1

[back to top]

LTSE: Median Percent Change In Total Bilirubin From Baseline To Last Available Visit

As a marker of hepatocellular injury and liver function, the percent change in total bilirubin from baseline to the last available visit is reported. The DB baseline value was used as the baseline. (NCT00570765)
Timeframe: Baseline (DB), Last Available Visit (up to 96 months)

InterventionPercent Change (Median)
LTSE OCA Total5.2

[back to top]

Colonic Filling at 6 Hours

Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time. (NCT00912301)
Timeframe: after 4 days' treatment

Interventionpercentage of the radio-labeled meal (Mean)
NaCDC 500 mg52.6
NaCDC 1000 mg54.8
Placebo50.6

[back to top]

Ascending Colon Emptying (AC t_1/2)

(NCT00912301)
Timeframe: after 4 days' treatment

Interventionhours (Mean)
NaCDC 500 mg9.5
NaCDC 1000 mg8.2
Placebo15.8

[back to top]

Stool Consistency

"The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the ideal stools especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea." (NCT00912301)
Timeframe: after 4 days' treatment

Interventionunits on a scale (Mean)
NaCDC 500 mg4.4
NaCDC 1000 mg4.4
Placebo2.9

[back to top]

Colonic Transit at 48 Hours (GC48)

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (NCT00912301)
Timeframe: after 4 days of treatment

Interventionunits on a scale (Mean)
NaCDC 500 mg4.1
NaCDC 1000 mg4.3
Placebo3.8

[back to top]

Colonic Geometric Center at 24 Hours (GC24)

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (NCT00912301)
Timeframe: after 4 days of treatment

Interventionunits on a scale (Mean)
NaCDC 500 mg3.1
NaCDC 1000 mg3.5
Placebo2.2

[back to top]

Steatosis: Change in Score

Change in steatosis score. Steatosis was assessed on a scale of 0-3, with higher scores showing more severe steatosis. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid-0.8
Placebo-0.4

[back to top]

Steatosis: Patients With Improvement

Patients with improvement in steatosis score. Steatosis was assessed on a scale of 0-3, with higher scores showing more severe steatosis. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid62
Placebo37

[back to top]

Total NAFLD Activity Score: Change in Score

NAFLD activity score was assessed on a scale of 0-8, with higher scores showing more severe disease (the components of this measure are steatosis [assessed on a scale of 0-3], lobular inflammation [assessed on a scale of 0-3], and hepatocellular ballooning [assessed on a scale of 0-2]). (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid-1.7
Placebo-0.7

[back to top]

Change in Haematocrit

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionproportion of 1.0 (Mean)
Obeticholic Acid0.00
Placebo0.00

[back to top]

Change in γ-glutamyl Transpeptidase

(NCT01265498)
Timeframe: baseline to 72 weeks

InterventionU/L (Mean)
Obeticholic Acid-37
Placebo-6

[back to top]

Fibrosis: Change in Score

Change in fibrosis score. Fibrosis was assessed on a scale of 0-4, with higher scores showing more severe fibrosis. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid-0.2
Placebo0.1

[back to top]

Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)

"Centrally scored histological improvement in nonalcoholic fatty liver disease (NAFLD) from baseline to the end of 72 weeks of treatment, where improvement is defined as:~No worsening in fibrosis; and~A decrease in NAFLD Activity Score (NAS) of at least 2 points" (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid50
Placebo23

[back to top]

Fibrosis: Patient With Improvement

Patients with improvement in fibrosis score. Fibrosis was assessed on a scale of 0-4, with higher scores showing more severe fibrosis. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid36
Placebo19

[back to top]

Hepatocellular Ballooning: Change in Score

Change in hepatocellular ballooning score. Hepatocellular ballooning was assessed on a scale of 0-2, with higher scores showing more severe ballooning. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid-0.5
Placebo-0.2

[back to top]

Hepatocellular Ballooning: Patients With Improvement

Patients with improvement in hepatocellular ballooning score. Hepatocellular ballooning was assessed on a scale of 0-2, with higher scores showing more severe ballooning. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid47
Placebo30

[back to top]

Lobular Inflammation: Change in Score

Change in lobular inflammation score. Lobular inflammation was assessed on a scale of 0-3, with higher scores showing more severe lobular inflammation. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid-0.5
Placebo-0.2

[back to top]

Lobular Inflammation: Patients With Improvement

Patients with improvement in lobular inflammation score. Lobular inflammation was assessed on a scale of 0-3, with higher scores showing more severe lobular inflammation. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid54
Placebo34

[back to top]

Portal Inflammation: Change in Score

Change in portal inflammation score. Portal inflammation was assessed on a scale of 0-3, with higher scores showing more severe portal inflammation. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid0.2
Placebo0.2

[back to top]

Change in Body-mass Index

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionkg/m² (Mean)
Obeticholic Acid-0.7
Placebo0.1

[back to top]

Portal Inflammation: Patients With Improvement

Patients with improvement in portal inflammation score. Portal inflammation was assessed on a scale of 0-2, with higher scores showing more severe portal inflammation. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid12
Placebo13

[back to top]

Resolution of NASH Diagnosis

Resolution of definite nonalcoholic steatohepatitis. Resolution defined as either not NAFLD, or NAFLD but not non-alcoholic steatohepatitis on week 72 biopsy (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionparticipants (Number)
Obeticholic Acid22
Placebo13

[back to top]

Change in Alanine Aminotransferase

(NCT01265498)
Timeframe: baseline to 72 weeks

InterventionU/L (Mean)
Obeticholic Acid-38
Placebo-18

[back to top]

Change in Albumin

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventiongl/L (Mean)
Obeticholic Acid-0.2
Placebo0.3

[back to top]

Change in Alkaline Phosphatase

(NCT01265498)
Timeframe: baseline to 72 weeks

InterventionU/L (Mean)
Obeticholic Acid12
Placebo-6

[back to top]

Change in Asparate Aminotransferase

(NCT01265498)
Timeframe: baseline to 72 weeks

InterventionU/L (Mean)
Obeticholic Acid-27
Placebo-10

[back to top]

Change in Bicarbonate

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid-0.7
Placebo-0.1

[back to top]

Change in Insulin

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionpmol/L (Mean)
Obeticholic Acid29
Placebo10

[back to top]

Change in Calcium

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid0.01
Placebo-0.01

[back to top]

Change in Creatinine

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionμmol/L (Mean)
Obeticholic Acid1.5
Placebo-1.1

[back to top]

Change in Diastolic Blood Pressure

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmm Hg (Mean)
Obeticholic Acid0
Placebo0

[back to top]

Change in Fasting Serum Glucose

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid0.4
Placebo0.2

[back to top]

Change in Glycated Haemoglobin A1c

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/mol (Mean)
Obeticholic Acid0.5
Placebo0.4

[back to top]

Change in Haemoglobin

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventiong/L (Mean)
Obeticholic Acid0.6
Placebo0.3

[back to top]

Change in HDL Cholesterol

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid-0.02
Placebo0.03

[back to top]

Change in HOMA-IR

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionglucose[mmol/L]× insulin[pmol/L] / 22.5 (Mean)
Obeticholic Acid15
Placebo4

[back to top]

Change in International Normalised Ratio

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionratio (Mean)
Obeticholic Acid-0.03
Placebo0.00

[back to top]

Change in LDL Cholesterol

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid0.22
Placebo-0.22

[back to top]

Change in Mean Corpuscular Volume

(NCT01265498)
Timeframe: baseline to 72 weeks

InterventionfL (Mean)
Obeticholic Acid-0.8
Placebo0.3

[back to top]

Change in Phosphate

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid0.01
Placebo0.02

[back to top]

Change in Platelet Count

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionplatelets *10^9 per L (Mean)
Obeticholic Acid12
Placebo-4

[back to top]

Change in Prothrombin Time

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventions (Mean)
Obeticholic Acid-0.1
Placebo0.0

[back to top]

Change in SF-36 Quality of Life Mental Component Summary

Short Form (36) Health Survey The SF-36 evaluates health-related quality of life in 8 domains consisting of two components: physical and mental. The score for each domain ranges from 0 to 100. Norm based scoring (based on the general US population) is used with a mean of 50 and standard deviation of 10. Higher values represent a better outcome. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid0
Placebo1

[back to top]

Change in SF-36 Quality of Life Physical Component Summary

Short Form (36) Health Survey The SF-36 evaluates health-related quality of life in 8 domains consisting of two components: physical and mental. The score for each domain ranges from 0 to 100. Norm based scoring (based on the general US population) is used with a mean of 50 and standard deviation of 10. Higher values represent a better outcome. (NCT01265498)
Timeframe: baseline to 72 weeks

Interventionunits on a scale (Mean)
Obeticholic Acid0
Placebo-1

[back to top]

Change in Systolic Blood Pressure

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmm Hg (Mean)
Obeticholic Acid-4
Placebo-1

[back to top]

Change in Total Bilirubin

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionμmol/L (Mean)
Obeticholic Acid-1.0
Placebo0.6

[back to top]

Change in Total Cholesterol

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid0.16
Placebo-0.19

[back to top]

Change in Total Protein

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventiongl/L (Mean)
Obeticholic Acid0.2
Placebo-0.5

[back to top]

Change in Triglycerides

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionmmol/L (Mean)
Obeticholic Acid-0.22
Placebo-0.08

[back to top]

Change in Uric Acid

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionμmol/L (Mean)
Obeticholic Acid2
Placebo-11

[back to top]

Change in Waist Circumference

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventioncm (Mean)
Obeticholic Acid-1.5
Placebo-0.6

[back to top]

Change in Waist-to-hip Ratio

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionratio (Mean)
Obeticholic Acid0.00
Placebo0.00

[back to top]

Change in Weight

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionkg (Mean)
Obeticholic Acid-2.3
Placebo0.0

[back to top]

Change in White Blood Cell Count

(NCT01265498)
Timeframe: baseline to 72 weeks

Interventionwhite blood cells *10^9 per L (Mean)
Obeticholic Acid0.0
Placebo0.0

[back to top]

LTSE Phase: Composite Endpoint ALP And Total Bilirubin

Percentage of participants at Months 24, 36, 48, and 60 with ALP < 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. DB Month 12 is the baseline for the LTSE phase. (NCT01473524)
Timeframe: Baseline (DB Month 12), LTSE Months 24, 36, 48, and 60

,,,
Interventionpercentage of participants (Number)
Baseline (Double-blind Month 12)LTSE Month 12LTSE Month 24LTSE Month 36LTSE Month 48LTSE Month 60
LTSE OCA (DB OCA 10 mg)565861515552
LTSE OCA (DB OCA 5-10 mg)515560485248
LTSE OCA (DB Placebo)94154496050
Overall LTSE OCA385158495650

[back to top]

LTSE Phase: ALP Levels

Blood samples were evaluated for ALP levels. (NCT01473524)
Timeframe: LTSE Day 0 and LTSE Months 12, 24, 36, 48, and 60

,,,
InterventionU/L (Mean)
LTSE Day 0LTSE Month 12LTSE Month 24LTSE Month 36LTSE Month 48LTSE Month 60
LTSE OCA (DB OCA 10 mg)191.24198.68194.57214.66192.00191.37
LTSE OCA (DB OCA 5-10 mg)218.69209.49195.14204.52189.75200.90
LTSE OCA (DB Placebo)317.79226.28215.99205.37198.70209.38
Overall LTSE OCA243.75211.47201.47208.27193.38200.94

[back to top]

LTSE Phase: ALP Change From DB Baseline

Blood samples were evaluated for ALP levels. ALP Change From Baseline (ALP at LTSE Months 12, 24, 36, 48, and 60 - ALP at Baseline) is presented. DB baseline is the mean of all available evaluations prior to DB treatment. (NCT01473524)
Timeframe: DB Baseline, LTSE Months 12, 24, 36, 48, and 60

,,,
InterventionU/L (Mean)
Month 12Month 24Month 36Month 48Month 60
LTSE OCA (DB OCA 10 mg)-104.39-102.52-84.65-101.50-117.49
LTSE OCA (DB OCA 5-10 mg)-106.63-120.86-100.98-118.23-118.99
LTSE OCA (DB Placebo)-104.36-100.99-112.73-115.51-119.52
Overall LTSE OCA-105.13-108.34-98.96-111.49-118.74

[back to top]

DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12

Blood samples were evaluated for bilirubin levels. Total bilirubin absolute change from baseline (total bilirubin at Month 12 - total bilirubin at Baseline) is presented. (NCT01473524)
Timeframe: Baseline, DB Month 12

Interventionumol/L (Least Squares Mean)
DB OCA 5-10 mg-0.33
DB OCA 10 mg-0.90
DB Placebo1.98

[back to top]

DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12

Blood samples were evaluated for GGT levels. GGT absolute change from baseline (GGT at Month 12 - GGT at Baseline) is presented. (NCT01473524)
Timeframe: Baseline, DB Month 12

InterventionU/L (Least Squares Mean)
DB OCA 5-10 mg-140.83
DB OCA 10 mg-176.66
DB Placebo6.70

[back to top]

DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12

Blood samples were evaluated for bilirubin levels. Direct bilirubin absolute change from baseline (direct bilirubin at Month 12 - direct bilirubin at Baseline) is presented. (NCT01473524)
Timeframe: Baseline, DB Month 12

Interventionumol/L (Least Squares Mean)
DB OCA 5-10 mg-0.13
DB OCA 10 mg-0.49
DB Placebo1.89

[back to top]

DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo

Percentage of participants at Month 6 with ALP < 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. (NCT01473524)
Timeframe: DB Month 6

Interventionpercentage of participants (Number)
DB OCA 5-10 mg34
DB Placebo7

[back to top]

DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo

Percentage of participants at Month 12 with ALP < 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. (NCT01473524)
Timeframe: DB Month 12

Interventionpercentage of participants (Number)
DB OCA 5-10 mg46
DB Placebo10

[back to top]

DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo

Percentage of participants at Month 12 with ALP < 1.67 x upper limit of normal (ULN) and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. (NCT01473524)
Timeframe: DB Month 12

Interventionpercentage of participants (Number)
DB OCA 10 mg47
DB Placebo10

[back to top]

DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12

Blood samples were evaluated for AST levels. AST absolute change from baseline (AST at Month 12 - AST at Baseline) is presented. (NCT01473524)
Timeframe: Baseline, DB Month 12

InterventionU/L (Least Squares Mean)
DB OCA 5-10 mg-13.03
DB OCA 10 mg-15.00
DB Placebo1.04

[back to top]

DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12

Blood samples were evaluated for ALT levels. ALT absolute change from baseline (ALT at Month 12 - ALT at Baseline) is presented. (NCT01473524)
Timeframe: Baseline, DB Month 12

InterventionU/L (Least Squares Mean)
DB OCA 5-10 mg-21.26
DB OCA 10 mg-25.31
DB Placebo-4.95

[back to top]

DB Phase: ALP Absolute Change From Baseline To Month 12

Blood samples were evaluated for ALP levels. ALP Absolute Change From Baseline (ALP at Month 12 - ALP at Baseline) is presented. (NCT01473524)
Timeframe: Baseline, DB Month 12

InterventionU/L (Least Squares Mean)
DB OCA 5-10 mg-112.51
DB OCA 10 mg-129.90
DB Placebo-14.42

[back to top]

DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo

Percentage of participants at Month 6 with ALP < 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. (NCT01473524)
Timeframe: DB Month 6

Interventionpercentage of participants (Number)
Double-blind OCA 10 mg51
Double-blind Placebo7

[back to top]

Changes in Fasting 7α-hydroxy-4-cholesten-3-one

Change in fasting 7α-hydroxy-4-cholesten-3-one before and after 15 day administration of OCA. (NCT01585025)
Timeframe: Day 0, Day 15

Interventionmicrogram/L (Median)
Primary BAD-11.5
Secondary BAD-27.5
Idiopathic Diarrhoea Controls-6.5

[back to top]

Changes in Fasting FGF19

The primary outcome measure is the change over 2 weeks in fasting serum fibroblast growth factor (FGF19) in 3 groups of patients: primary bile acid diarrhoea, secondary bile acid diarrhoea, and a control population of patients with chronic diarrhoea but with normal bile acid retention. (NCT01585025)
Timeframe: Day 0, Day 15

Interventionpercentage increase of baseline (Median)
Primary BAD71
Secondary BAD25
Idiopathic Diarrhoea Controls130

[back to top]

Changes in Mean Stool Form

Change in mean stool form reported per week between week 2 (baseline) and week 4 (week 2 of treatment) using the Bristol Stool Form Scale (range of scores 1 to 7). High scores are a worse outcome (7=liquid stools). (NCT01585025)
Timeframe: Week 2, Week 4

InterventionScore on Bristol scale (Median)
Primary BAD-0.71
Secondary BAD-0.38
Idiopathic Diarrhoea Controls-0.46

[back to top]

Changes in Non-fasting Response of FGF19 to OCA

Change in dynamic response of FGF19 in 6 hours following OCA administration; at start and end of 15 day OCA test period. (NCT01585025)
Timeframe: Day 0, Day 15

Interventionpercentage change (Median)
Primary BAD11.6
Secondary BAD14.6
Idiopathic Diarrhoea Controls32.4

[back to top]

Changes in Serum Total Bile Acids.

Dynamic changes of total bile acids over 6 hour period following OCA administration before and after 15 day OCA period. (NCT01585025)
Timeframe: Day 0, Day 15

Interventionmicromol/L (Median)
Primary BAD-18.1
Secondary BAD-2.0
Idiopathic Diarrhoea Controls-15.5

[back to top]

Changes in Stool Frequency

Change in total number of stool episodes reported per week between week 2 (baseline) and week 4 (week 2 of treatment) (NCT01585025)
Timeframe: Week 2, Week 4

Interventionstools per week (Median)
Primary BAD-4.5
Secondary BAD-2.5
Idiopathic Diarrhoea Controls3.0

[back to top]

Change in Stool Index

"Change in index calculated on a weekly basis, between week 2 (baseline) and week 4 (week 2 of treatment).~Index calculated as ([weekly stool frequency x mean Bristol Stool Form Scale score] = Loperamide use [weekly mg x 3]).~Individual scores ranged from 25 to 1095, with higher scores being worst." (NCT01585025)
Timeframe: Week 2, Week 4

Interventionindex score (Median)
Primary BAD-37.5
Secondary BAD-32.5
Idiopathic Diarrhoea Controls-5.5

[back to top]

Median Change From Baseline In Macrophage Cholesterol Efflux

Results are reported as a percentage of cholesterol. (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT

Interventionpercentage of cholesterol (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-1.745-1.940-2.450-0.770

[back to top]

Median Change From Baseline In Prebeta-1 HDL Concentration

Results are reported in microgram/milliliter (ug/mL). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT

Interventionug/mL (Median)
Week 4Week 8
Primary Treatment Phase1.557.55

[back to top]

Median Change From Baseline In Prebeta-1 HDL Concentration

Results are reported in microgram/milliliter (ug/mL). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT

Interventionug/mL (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-6.90-10.051.94-1.35

[back to top]

Median Change From Baseline In Prothrombin International Normalized Ratio

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionratio (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase0.00000.00000.00000.0000

[back to top]

Median Change From Baseline In Prothrombin Time

Results are reported in seconds (sec). (NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionsec (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase0.000-0.0500.4000.200

[back to top]

Median Change From Baseline In Tissue Inhibitor Of Metalloproteinases 1

(NCT01865812)
Timeframe: Baseline, Month 12, Month 24/EOT

Interventionug/L (Median)
Month 12Month 24/EOT
Long-term Safety Extension Phase9.6002.000

[back to top]

Median Change From Baseline In Total And Unconjugated (Direct) Bilirubin

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase0.00000.00000.00000.0000

[back to top]

Median Change From Baseline In Total Bile Acids

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-1.56-1.14-4.61-4.91

[back to top]

Median Change From Baseline In Total Chenodeoxycholic Acid

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-0.20-0.35-1.28-1.17

[back to top]

Median Change From Baseline In Total Cholesterol

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmmol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-0.0518-0.28490.2331

[back to top]

Median Change From Baseline In Total Cholesterol

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmmol/L (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-0.18130.07770.2849-0.07770.285

[back to top]

Median Change From Baseline In Total Cholic Acid

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-0.39-0.48-0.49-0.39

[back to top]

Median Change From Baseline In Total Deoxycholic Acid

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-0.59-0.56-0.51-0.59

[back to top]

Median Change From Baseline In C-reactive Protein

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionnmol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase0.00000.000011.4288

[back to top]

Median Change From Baseline In Total Endogenous Bile Acid

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-0.83-0.77-2.19-2.02

[back to top]

Median Change From Baseline In Total LDL Particles

Results are reported in nanomoles per liter (nmol/L). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnmol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase108.0128.0159.0

[back to top]

Median Change From Baseline In Total Lithocholic Acid

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase0.000.000.000.00

[back to top]

Median Change From Baseline In Total Triglycerides

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmmol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-0.02260.05650.1130

[back to top]

Median Change From Baseline In Total Triglycerides

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmmol/L (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-0.1469-0.0113-0.05650.000-0.068

[back to top]

Median Change From Baseline In Total UDCA

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-0.34-0.47-2.89-1.68

[back to top]

Median Change From Baseline In Very Low-density Lipoprotein (VLDL) Cholesterol

Results are reported in milligrams per deciliter (mg/dL). (NCT01865812)
Timeframe: Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmg/dL (Median)
Week 12
Primary Treatment Phase5.0

[back to top]

Median Change From Baseline In Very Low-density Lipoprotein (VLDL) Cholesterol

Results are reported in milligrams per deciliter (mg/dL). (NCT01865812)
Timeframe: Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmg/dL (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-21.0-7.0-14.0-1.0-11.5

[back to top]

Median Change From Baseline In VLDL Particle Size

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnm (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase42.5543.4045.10

[back to top]

Median Change From Baseline In VLDL Particle Size

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnm (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-4.80-3.50-4.900.50-4.10

[back to top]

Median Change From Baseline In VLDL Particles

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnmol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-5.552.70-0.90

[back to top]

Median Change From Baseline In VLDL Particles

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnmol/L (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-4.70-6.20-6.80-0.30-6.80

[back to top]

Participants With Lipoprotein X

Lipoprotein samples were assessed using nuclear magnetic resonance spectroscopy for the presence/absence of Lipoprotein X. Lipoprotein X sometimes appears with advanced cholestasis and can confound assessment of other lipoprotein concentrations, particularly LDL. (NCT01865812)
Timeframe: Week 12 and Last Dose

,
InterventionParticipants (Count of Participants)
Week 12Last Dose
Long-term Safety Extension Phase00
Primary Treatment Phase10

[back to top]

Time To Reach Cmax (Tmax) For OCA And Conjugates

Results are reported in hours (h). (NCT01865812)
Timeframe: Week 8

Interventionh (Median)
OCAGlyco-OCATauro-OCATotal-OCA
Primary Treatment Phase1.005.005.985.00

[back to top]

Absolute Change From Baseline In HDL Cholesterol Concentration

(NCT01865812)
Timeframe: Baseline, Month 24/EOT

Interventionmmol/L (Least Squares Mean)
Long-term Safety Extension Phase0.5

[back to top]

Absolute Change From Baseline In HDL Particle Number

(NCT01865812)
Timeframe: Baseline, Month 24/EOT

Interventionumol/L (Least Squares Mean)
Long-term Safety Extension Phase-0.09

[back to top]

Absolute Change From Baseline In HDL Particle Number

(NCT01865812)
Timeframe: Baseline, Week 8

Interventionumol/L (Least Squares Mean)
Primary Treatment Phase-0.06

[back to top]

Absolute Change From Baseline In HDL Particle Size

(NCT01865812)
Timeframe: Baseline, Month 24/EOT

Interventionnm (Least Squares Mean)
Long-term Safety Extension Phase0.04

[back to top]

Absolute Change From Baseline In HDL Particle Size

(NCT01865812)
Timeframe: Baseline, Week 8

Interventionnm (Least Squares Mean)
Primary Treatment Phase-0.44

[back to top]

Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration

(NCT01865812)
Timeframe: Baseline, Week 8

Interventionmmol/L (Least Squares Mean)
Primary Treatment Phase-0.38

[back to top]

Median Change From Week 8 In HDL Cholesterol Concentration At Week 12

(NCT01865812)
Timeframe: Week 8, Week 12

Interventionmmol/L (Median)
Primary Treatment Phase0.3108

[back to top]

Median Change From Week 8 In HDL Particle Number At Week 12

(NCT01865812)
Timeframe: Week 8, Week 12

Interventionumol/L (Median)
Primary Treatment Phase1.40

[back to top]

Median Change From Week 8 In HDL Particle Size At Week 12

(NCT01865812)
Timeframe: Week 8, Week 12

Interventionnm (Median)
Primary Treatment Phase0.30

[back to top]

Area Under The Concentration-time Curve From Hour 0 To Last Sampling Time (Hour 6) (AUC0-6) For OCA And Conjugates

Results are reported in hour*nanograms per milliliter (h*ng/mL). (NCT01865812)
Timeframe: Week 8

Interventionh*ng/mL (Mean)
OCAGlyco-OCATauro-OCATotal-OCA
Primary Treatment Phase1897026981360

[back to top]

Maximum Plasma Concentration (Cmax) Of OCA And Conjugates

Results are reported in nanograms per milliliter (ng/mL). (NCT01865812)
Timeframe: Week 8

Interventionng/mL (Mean)
OCAGlycine Conjugate (Glyco)-OCATaurine Conjugate (Tauro)-OCATotal-OCA
Primary Treatment Phase107212219409

[back to top]

Median Change From Baseline In Alanine Aminotransferase

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

InterventionU/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-9.80-9.80-11.80-5.95

[back to top]

Median Change From Baseline In Albumin

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

Interventiong/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-0.60-0.201.300.05

[back to top]

Median Change From Baseline In Alkaline Phosphatase

Results are reported in units/Liter (U/L). (NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

InterventionU/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-43.40-31.50-31.906.40

[back to top]

Median Change From Baseline In Amino-terminal Propeptide Of Type III Procollagen

Results are reported in micrograms/Liter (ug/L). (NCT01865812)
Timeframe: Baseline, Month 12, Month 24/EOT

Interventionug/L (Median)
Month 12Month 24/EOT
Long-term Safety Extension Phase0.6702.095

[back to top]

Median Change From Baseline In ApoA1/ApoB Ratio

(NCT01865812)
Timeframe: Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

InterventionRatio (Median)
Week 12
Primary Treatment Phase-0.0503

[back to top]

Median Change From Baseline In ApoA1/ApoB Ratio

(NCT01865812)
Timeframe: Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

InterventionRatio (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-0.2174-0.1659-0.2860-0.1172-0.291

[back to top]

Median Change From Baseline In Apolipoprotein A1 (ApoA1)

Results are reported in grams per liter (g/L). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventiong/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-0.1000-0.06000.0400

[back to top]

Median Change From Baseline In Apolipoprotein A1 (ApoA1)

Results are reported in grams per liter (g/L). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventiong/L (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-0.1400-0.0900-0.10000.0100-0.045

[back to top]

Median Change From Baseline In Apolipoprotein B (ApoB)

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionunits on a scale (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase0.09500.07000.0500

[back to top]

Median Change From Baseline In Apolipoprotein B (ApoB)

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionunits on a scale (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase0.04000.04000.06000.09000.060

[back to top]

Median Change From Baseline In Apolipoprotein E

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmg/dL (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-0.85-0.650.50

[back to top]

Median Change From Baseline In Apolipoprotein E

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmg/dL (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-0.30-0.30-0.100.000.00

[back to top]

Median Change From Baseline In Aspartate Aminotransferase

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

InterventionU/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-5.30-3.60-6.00-4.50

[back to top]

Median Change From Baseline In Total LDL Particles

Results are reported in nanomoles per liter (nmol/L). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnmol/L (Median)
Month 6 (Small)Month 12 (Small)Month 18 (Small)Month 24/EOT (Small)Last Dose (Small)Month 6 (Large)Month 12 (Large)Month 18 (Large)Month 24/EOT (Large)Last Dose (Large)Month 6 (Intermediate-density Lipoprotein [IDL])Month 12 (IDL)Month 18 (IDL)Month 24/EOT (IDL)Last Dose (IDL)
Long-term Safety Extension Phase148.089.018.034.022.09.0-53.0-18.0-122.0-8.0-12.0-57.0-43.078.011.0

[back to top]

Median Change From Baseline In C-reactive Protein

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionnmol/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase0.000.000.000.00

[back to top]

Median Change From Baseline In Cholesteryl Ester Transfer Protein

Results are reported in picomole/milliliter/minute (pmol/mL/min). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionpmol/mL/min (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase1.950.304.70

[back to top]

Median Change From Baseline In Cholesteryl Ester Transfer Protein

Results are reported in picomole/milliliter/minute (pmol/mL/min). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionpmol/mL/min (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase1.20-0.600.500.40

[back to top]

Median Change From Baseline In Enhanced Liver Fibrosis (ELF) Score

"Change in ELF was calculated as ELF score at the end of the study minus ELF score prior to the intervention (at baseline). A decrease in the ELF score was considered good as it reflected a decrease in liver fibrosis, and an increase in ELF score was considered bad as it reflected an increase in liver fibrosis.~Change in ELF scores ranged from -0.56 (good) to + 0.68 (bad)." (NCT01865812)
Timeframe: Baseline, Month 12, Month 24/EOT

Interventionscore on a scale (Median)
Month 12Week 24/EOT
Long-term Safety Extension Phase0.0000.150

[back to top]

Median Change From Baseline In Fibroblast Growth Factor-19

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionpg/mL (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase81.8800112.546016.8400

[back to top]

Median Change From Baseline In Fibroblast Growth Factor-19

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionpg/mL (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase81.39029.22055.230-0.740

[back to top]

Median Change From Baseline In Gamma-glutamyl Transferase

(NCT01865812)
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24/EOT

InterventionU/L (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-59.40-41.60-40.80-30.05

[back to top]

Median Change From Baseline In Glycoprotein A

Results are reported in picograms/milliliter (pg/mL). (NCT01865812)
Timeframe: Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionpg/mL (Median)
Week 12
Primary Treatment Phase12.0

[back to top]

Median Change From Baseline In Glycoprotein A

Results are reported in picograms/milliliter (pg/mL). (NCT01865812)
Timeframe: Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionpg/mL (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-27.0-13.0-26.010.0

[back to top]

Median Change From Baseline In HDL Cholesterol Concentration At Weeks 4, 8, and 12

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8, Week 12

Interventionmmol/L (Median)
Week 4Week 8Week 12
Primary Treatment Phase-0.2072-0.31080.0518

[back to top]

Median Change From Baseline In HDL Particle Number At Weeks 4, 8, and 12

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8, Week 12

Interventionumol/L (Median)
Week 4Week 8Week 12
Primary Treatment Phase0.550.601.60

[back to top]

Median Change From Baseline In HDL Particle Size At Weeks 4, 8, and 12

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8, Week 12

Interventionnm (Median)
Week 4Week 8Week 12
Primary Treatment Phase-0.30-0.300.00

[back to top]

Median Change From Baseline In Hepatic Stiffness

Results are reported in kilopascal (kPa). (NCT01865812)
Timeframe: Baseline, Month 12, Month 24/EOT

InterventionkPa (Median)
Month 12Month 24/EOT
Long-term Safety Extension Phase-1.15-1.70

[back to top]

Median Change From Baseline In Hyaluronic Acid

(NCT01865812)
Timeframe: Baseline, Month 12, Month 24/EOT

Interventionng/mL (Median)
Month 12Month 24/EOT
Long-term Safety Extension Phase-5.700-1.805

[back to top]

Median Change From Baseline In LDL Particle Size

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnm (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-0.30-0.100.00

[back to top]

Median Change From Baseline In LDL Particle Size

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionnm (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase-0.10-0.20-0.10-0.10-0.10

[back to top]

Median Change From Baseline In Lecithin-cholesterol Acyltransferase Activity

Results are reported in nanomoles/milliliter/hour (nmol/mL/h). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionnmol/mL/h (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase-20.5-13.515.5

[back to top]

Median Change From Baseline In Lecithin-cholesterol Acyltransferase Activity

Results are reported in nanomoles/milliliter/hour (nmol/mL/h). (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT

Interventionnmol/mL/h (Median)
Month 6Month 12Month 18Month 24/EOT
Long-term Safety Extension Phase-47.046.0-19.0-56.0

[back to top]

Median Change From Baseline In Lipoprotein-a

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionumol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase0.00000.00000.0000

[back to top]

Median Change From Baseline In Lipoprotein-a

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionumol/L (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase0.00000.00000.00000.00000.000

[back to top]

Median Change From Baseline In Low-density Lipoprotein (LDL) Cholesterol (Direct)

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmmol/L (Median)
Week 4Week 8/EOTWeek 12
Primary Treatment Phase0.270.310.18

[back to top]

Median Change From Baseline In Low-density Lipoprotein (LDL) Cholesterol (Direct)

(NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose

Interventionmmol/L (Median)
Month 6Month 12Month 18Month 24/EOTLast Dose
Long-term Safety Extension Phase0.31080.44030.59570.31080.518

[back to top]

Median Change From Baseline In Macrophage Cholesterol Efflux

Results are reported as a percentage of cholesterol. (NCT01865812)
Timeframe: Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT

Interventionpercentage of cholesterol (Median)
Week 4Week 8
Primary Treatment Phase-0.800-0.705

[back to top]

Change in the Liver Triglycerides (TG).

The primary end-point variable was the change in the liver TG content assessed using proton-density fat fraction mapping by Magnetic Resonance Imaging (MRI). (NCT02430077)
Timeframe: Baseline, 4 months

Interventionpercentage of liver triglycerides (Median)
Baseline (Month 0)13.2
Obeticholic Acid (Month 4)6.4
Placebo (Month 0)12.3
Placebo (Month 4)10.6

[back to top]

Change in Serum Triglyceride Levels

Change in the serum levels of Triglycerides from baseline to month 4 is being assessed. (NCT02430077)
Timeframe: Baseline, Month 4

Interventionmg/dL (Median)
Baseline (Month 0)199.2
Obeticholic Acid (Month 4)182.3
Placebo (Month 0)169.3
Placebo (Month 4)161.3

[back to top]

Change in Serum Levels of Gamma-Glutamyl Transpeptidase

Change in serum levels of Gamma-Glutamyl Transpeptidase from baseline to month 4 is assessed (NCT02430077)
Timeframe: Baseline, Month 4

InterventionU/L (Median)
Baseline (Month 0)27.5
Obeticholic Acid (Month 4)17
Placebo (Month 0)21.6
Placebo (Month 4)21.2

[back to top]

Change in Serum Levels of Aspartate Aminotransferases

Change in serum levels of Aspartate Aminotransferases from baseline to month 4 is assessed (NCT02430077)
Timeframe: Baseline, Month4

InterventionU/L (Median)
Baseline (Month 0)15.5
Obeticholic Acid (Month 4)16.8
Placebo (Month 0)18.7
Placebo (Month 4)16.5

[back to top]

Change in Serum Levels of Alanine Aminotransferase

Change in serum levels of Alanine Aminotransferase from baseline to month 4 is assessed (NCT02430077)
Timeframe: Baseline, Month 4

InterventionU/L (Median)
Baseline (Month 0)16.3
Obeticholic Acid (Month 4)15.8
Placebo (Month 0)19.0
Placebo (Month 4)18.5

[back to top]

Change in C4 Total Area Under the Curve From Baseline Before Versus After Cholecystectomy

Change in total AUC for C4 between visit 1 and visit 2 (NCT03168555)
Timeframe: before cholecystectomy and 3-5 months after cholecystectomy

Interventionng/mL x minutes (Mean)
Visit 1774
Visit 21040

[back to top]

Change in Chenodeoxycholic Acid (CDCA) Absorption to Plasma From Baseline Before Versus After Cholecystectomy

Change from baseline to after cholecystectomy in median unconjugated CDCA plus meal stimulated absorption of unconjugated CDCA to measured in plasma (total area under the CDCA curve with measurement at fasting ie. t=0 minutes and subsequently at 60, 90, 120, and finally at 150minutes. (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

InterventionµM * minutes (Median)
Visit 11554
Visit 21847

[back to top]

Change in Fasting 7-alpha-hydroxy-cholestenone (C4) From Baseline Before Versus After Cholecystectomy

Change from baseline to after cholecystectomy in fasting C4 (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

Interventionng/mL (Mean)
Visit 16.0
Visit 27.5

[back to top]

Change in Fasting FGF19 From Baseline Before Versus After Cholecystectomy

change in fasting FGF19 before versus after cholecystectomy (NCT03168555)
Timeframe: before and 3-5 months after cholecystectomy

Interventionpg per mL (Mean)
Visit 1102
Visit 292

[back to top]

Change in Lipid Status From Baseline Before Versus After Cholecystectomy

Change from baseline to after cholecystectomy in plasma triglycerides (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

Interventionmmol/L (Median)
Visit 11.4
Visit 21.5

[back to top]

Change in Patient Reported Diarrhea Symptoms Correlated With Change in C4 From Baseline Before Versus After Cholecystectomy

Correlation between patient reported frequency of diarrhea (gastrointestinal quality of life index item 31) and fasting C4 before versus after cholecystectomy (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

InterventionSpearman correlation coefficient (Number)
Visit 1-.23
Visit 2-0.52

[back to top]

Change in Patient Reported Diarrhea Symptoms Correlated With Change in FGF19 From Baseline Before Versus After Cholecystectomy

Correlation between patient reported frequency of diarrhea (gastrointestinal quality of life index item 31) and fasting FGF19 before versus after cholecystectomy (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

InterventionSpearman correlation coefficient (Number)
Visit 10.08
Visit 2-0.07

[back to top]

Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy

Change from baseline to after cholecystectomy in median chenodeoxycholic acid (CDCA) plus meal stimulated FGF19 (delta 0 min to 150 min after stimulation) (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

Interventionpg per mL (Median)
Visit 181
Visit 2186

[back to top]

Change in Stool Consistency (Bristol Stool Type) From Baseline Before Versus After Cholecystectomy

Change from baseline to after cholecystectomy in mean Bristol type per stool as of a seven-day diary baseline versus after cholecystectomy. The Bristol scale divides stool into seven categories from 1 (hard lumps) to 7 (completely watery stool). The diary shows pictograms with short text descriptions. (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

InterventionBristol stool type (Median)
Visit 14.2
Visit 24.0

[back to top]

Change in Stool Frequency From Baseline Before Versus After Cholecystectomy

Change from baseline to after cholecystectomy in number of stools as a mean of a seven-day diary baseline versus after cholecystectomy. That is the diary results for each study participant is tallied using mean values. The tallying of these diary results is done using medians. Therefore the unit used is 'mean stools per day' and this is reported with medians (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

Interventionmean stools per day (Median)
Visit 11.6
Visit 21.6

[back to top]

Change in Stool Pattern Correlated to FGF19

Spearman correlation between change from baseline to after cholecystectomy in FGF19 and in mean number of stools (NCT03168555)
Timeframe: baseline and 3 - 5 months after cholecystectomy

InterventionSpearman correlation coefficient (Number)
Intervention-0.21

[back to top]

DB Phase: Change From Baseline to Month 18 in LSM

Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled TE method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. The principal comparison was at Month 18. Baseline was defined as the last value collected prior to the first administration of the IP. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03439254)
Timeframe: Baseline and up to Month 18

InterventionKilopascal (kPa) (Median)
DB: Placebo-0.50
DB: OCA 10 Milligrams (mg)-3.10
DB: OCA 10 mg Titrated to OCA 25 mg-2.90

[back to top]

OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. (NCT03439254)
Timeframe: Up to 12 months

,,
InterventionParticipants (Count of Participants)
AEsSAEs
OLE: OCA 10 mg (DB OCA 10 mg)21350
OLE: OCA 10 mg (DB Placebo)19926
OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)19748

[back to top] [back to top] [back to top]

OLE Phase: Number of Participants Reporting All-cause Mortality

All-cause mortality is defined as death due to any cause. Number of participants reporting all-cause mortality is presented (NCT03439254)
Timeframe: Up to Month 12

InterventionParticipants (Count of Participants)
OLE: OCA 10 mg (DB Placebo)1
OLE: OCA 10 mg (DB OCA 10 mg)0
OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)1

[back to top]

OLE Phase: Fibrosis-4 (FIB-4) at Baseline

FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, alanine aminotransferase (ALT) and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, Aspartate aminotransferase (AST) and age that was calculated using formula: FIB-4 = (Age [years] x AST [Units per Liter {U/L}]) / (platelets [10^9/L] x (square root of ALT [U/L])). A FIB-4 index of <1.45 indicated no or moderate fibrosis and an index of > 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP. (NCT03439254)
Timeframe: Baseline (Day 1)

InterventionRatio (Mean)
OLE: OCA 10 mg (DB Placebo)2.179
OLE: OCA 10 mg (DB OCA 10 mg)2.267
OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)2.266

[back to top]

OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline

ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP1) and procollagen III N-terminal peptide (PIIINP). Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: < 7.7: no to mild fibrosis; ≥ 7.7 - < 9.8: Moderate fibrosis; ≥ 9.8 - < 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP. (NCT03439254)
Timeframe: Baseline (Day 1)

InterventionScores on a scale (Mean)
OLE: OCA 10 mg (DB Placebo)10.46
OLE: OCA 10 mg (DB OCA 10 mg)10.50
OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)10.48

[back to top]

OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)

Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled transient elastography (TE) method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. Baseline was defined as the last value collected prior to the first administration of the investigational product (IP). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. (NCT03439254)
Timeframe: Baseline and up to Month 12

InterventionKilopascal (kPa) (Median)
OLE: OCA 10 mg (DB Placebo)-2.10
OLE: OCA 10 mg (DB OCA 10 mg)-2.90
OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)-3.45

[back to top]

DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)

Fibrosis stage was evaluated by NASH Clinical Research Network(CRN)Fibrosis Staging System with stages:0=no fibrosis;1=perisinusoidal/periportal;1A=mild,zone 3,perisinusoidal;1B=moderate,zone 3,perisinusoidal;1C=portal/periportal;2=perisinusoidal and portal/periportal;3=bridging fibrosis;4=cirrhosis.No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalcoholic fatty liver disease activity score (NAS) categories.NAS is semiquantitative scoring system based on unweighted sum of:steatosis (0=<5% to 3=>66%),lobular inflammation(0=no foci to 3=>4 foci/200x),hepatocellular ballooning(0=none to 2=many cells/prominent ballooning)scores.Total scale range:0-12;0:no features of fatty liver disease and 12:highest degree of fatty liver disease.Higher scores:worse symptoms.Responders:did not discontinue treatment due to Adverse event(AE) or did not die and had evaluable post-Baseline biopsy assessment (NCT03439254)
Timeframe: Up to 18 months

InterventionParticipants (Count of Participants)
DB: Placebo31
DB: OCA 10 Milligrams (mg)33
DB: OCA 10 mg Titrated to OCA 25 mg37

[back to top]

DB Phase: FIB-4 at Baseline

FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, ALT and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, AST and age that was calculated using formula: FIB-4 = (Age [years] x AST [U/L]) / (platelets [10^9/L] x (square root of ALT [U/L])). A FIB-4 index of <1.45 indicated no or moderate fibrosis and an index of > 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP. (NCT03439254)
Timeframe: Baseline (Day 1)

InterventionRatio (Mean)
DB: Placebo2.279
DB: OCA 10 Milligrams (mg)2.475
DB: OCA 10 mg Titrated to OCA 25 mg2.405

[back to top]

DB Phase: ELF at Baseline

ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised HA, TIMP1 and PIIINP. Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: < 7.7: no to mild fibrosis; ≥ 7.7 - < 9.8: Moderate fibrosis; ≥ 9.8 - < 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP. (NCT03439254)
Timeframe: Baseline (Day 1)

InterventionScores on a scale (Mean)
DB: Placebo10.50
DB: OCA 10 Milligrams (mg)10.60
DB: OCA 10 mg Titrated to OCA 25 mg10.61

[back to top] [back to top]